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Dengue virus (DENV) is a mosquito-borne flavivirus and infects 
approximately 400 million people annually. Currently, there are no 
approved vaccines or therapeutics available. Recent clinical trials of a 
tetravalent vaccine revealed a low efficacy, especially against DENV2. 
Here I have characterized two DENV2-specific neutralizing HMAbs. By 
using a combination of X-ray crystallography, hydrogen-deuterium 
exchange mass spectrometry (HDX-MS), and cryo-electron microscopy 
(cryo-EM) single particle analysis techniques, the epitopes of HMAbs 
3F9 and 10.15 were identified to be localized at domain I and III of the 
envelope (E) protein, respectively. HMAb 3F9 was able to bind to the 
virus at 4oC. In comparison, efficient binding of HMAb 10.15 to the virus 
particles can be achieved only at higher temperatures, indicating E 
protein motion was required to expose the epitope on the virus. The 
cryo-EM structure of the Fab fragment of HMAb 3F9 complexed with a 
DENV2 clinical isolate PVP94/07 showed that at saturating antibody 
concentrations, 120 of the 180 copies of E proteins on the virus surface 
were bound by Fab fragments. In contrast, Fab 10.15 could only bind to 




potent against another DENV2 strain New Guinea C (NGC) and the 
binding of Fabs resulted in a higher number of broken particles. Unlike 
HMAb 3F9, which Fab fragment was as neutralizing as the full-length 
immunoglobulin G (IgG), IgG 10.15 was approximately 100-fold more 
potent than Fab 10.15. This was most likely due to the larger steric 
hindrance caused by the size of a whole immunoglobulin. This unique 
characteristic of the whole HMAb 10.15 could compensate for its low 
binding occupancy on the virus surface thus leading to its overall high 
potency. Together, these findings show the complexity of antibody - 
flavivirus interaction and provide valuable clues in the selection of 
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Chapter I. Literature review   
1.1 Dengue virus  
Dengue virus (DENV) was first independently isolated by Kimura et al. 
and Sabin et al back in the 1940s. It belongs to the virus genus 
Flavivirus of the family Flaviviridae, which also encompasses several 
other important human pathogens, such as West Nile virus (WNV), 
tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and 
Japanese encephalitis virus (JEV) (Fig. 1-1). As arboviruses (arthropod 
borne viruses), their main method of transmission is through the bite of 
infected arthropods (mosquito or tick). There are four serotypes of 
DENV, defined by their reactivity to anti-dengue antibodies. The 
nucleotide sequences of these serotypes share about 65% identity 
(Kuno et al., 1998). DENV can be further classified into genotypes 
within each serotype based on their nucleic acid sequences 
(Rico-Hesse, 1990, Rico-Hesse, 2003). The diameter of the DENV 
particles is about 50 nm and its surface glycoproteins are arranged in 
icosahedral symmetry. The glycoprotein shell surrounds the lipid bilayer 
membrane which encloses the nucleocapsid. The nucleocapsid 
consists of multiple copies of capsid proteins complexed with the 11Kb 





Figure 1-1 Phylogenetic tree of the family Flaviviridae. Flaviviridae 
composed of Flavivirus, Pestivirus, Pegivirus and Hepacivirus genera 
(Figure adapted from (Romero-Brey and Bartenschlager, 2014)). 
There are two distinct DENV transmission cycles: (1) an endemic 
and epidemic cycle involving human hosts and transmission mainly by 
Aedes aegypti and Aedes albopictus mosquitoes, and (2) a cycle in 
sylvatic habitats, involving non-human primate hosts and several 
different Aedes mosquitoes (Gubler, 1988). Phylogenetic analysis of 
both endemic/epidemic and sylvatic DENV strains suggests that the 




(Wang et al., 2000). Infected humans, in which the virus can propagate, 
serve as a source of the virus for uninfected mosquitoes. 
1.2 Characteristics of dengue  
Dengue virus infection typically causes a flu-like illness, which in 
rare cases, can develop into lethal complication called dengue 
hemorrhagic fever (DHF) or dengue shock syndrome (DSS). The 
symptoms start to appear after an incubation period of 3-14 days 
(Gubler, 1998). Dengue symptoms include fever, severe headache, 
pain behind the eyes, muscle and joint pains, nausea, vomiting, swollen 
glands or rash. Severe dengue is potentially fatal due to capillary 
leakage accompanied by thrombocytopenia, altered hemostasis, and 
liver damage (John et al., 2013). The pathogenesis of dengue remains 
unclear due to a complex interaction of viral and host factors. An 
infection with one dengue serotype renders lifelong protection against 
that particular serotype and short-term protection against the other 
serotypes. Secondary infection by a heterologous DENV serotype has 
been hypothesized as the greatest risk factor for severe dengue 
(Halstead, 1988).  




Dengue is endemic in tropical and subtropical regions, affecting half 
of the world’s human population, with explosive outbreaks occurring 
more and more frequently (Guzman et al., 2010). It is estimated that 
500,000 people with severe dengue require hospitalization annually and 
2.5% of the affected die, a large proportion of whom are children (WHO, 
2009). A recent estimate suggests that there are 390 million dengue 
infections each year with 96 million of them manifesting clinically (Bhatt 
et al., 2013). There is currently no approved specific treatment or 
vaccine for dengue. 
1.4 Structure of dengue virus  
Mature DENV particles has a spherical shape, and the virus surface 
is composed of 180 copies of envelope (E) proteins and the same 
number of membrane (M) proteins arranged in icosahedral symmetry. 
Envelope proteins form homodimers and a set of three homodimers lay 
parallel to each other, which forms a raft (Fig. 1-2d). There are 30 rafts 
on the virus surface. There are three individual E proteins (molecules 
(mols) A, B, C) in one asymmetric unit (Fig. 1-2d). They have different 
local chemical microenvironments. After viral RNA replication, dengue 




The virus surface contains pre-membrane (prM) protein, a precursor of 
the M protein (Lindenbach and Rice, 2003). The pr domain of the prM 
caps the fusion loop of E protein. This prevents the newly synthesized 
virus particles from fusing back into the cell during the maturation 
process (Li et al., 2008, Kostyuchenko et al., 2013) (Fig. 1-2b). The 
prM-E heterodimers are organized as trimers, each forming one of the 
60 spikes on the surface of the immature virion.  
 
Figure 1-2 The cryo-EM structures of mature and immature DENV. 
Surface view of the cryo-EM density map of immature virus (a) and 




0-200 Å; cyan, 201-235 Å; blue, 236 Å above. Organization of the 
surface proteins in the immature virus (b) and mature virus (d) 
structures. E protein mols A, B and C in an asymmetric unit are colored 
as green, red and blue, respectively. Symmetry-related E proteins are 
shown as grey surfaces, and prM proteins are shown as cyan surfaces. 
Black dotted triangles represent one asymmetric unit, the 5-, 3- and 
2-fold vertices are indicated. For the mature virus in (d), mols A, B and 
C are labelled, mols in the nearby asymmetric unit forming the other half 
of the raft are labeled as A’, B’ and C’. Cryo-EM map of the mature and 
immature viruses are based on EMDB entry 5520 and 2141, 
respectively. The fitted models of mature and immature viruses are from 
PDB code 3J27 and 4B03, respectively.  
The E protein layer of three DENV2 strains have been found to 
expand at elevated temperatures (Fibriansah et al., 2013, Zhang et al., 
2013). Four classes of particles have been observed at higher 
temperatures for the DENV2 New Guinea C (NGC) strain (Fibriansah et 
al., 2013) (Fig. 1-3). Class I particles are similar to the compact 
unexpanded DENV2 structure while, the class II and III particles have 
larger radius. The E protein shell of class IV particles was shown to lose 
icosahedral symmetry. Temperatures above 33oC (Zhang et al., 2013) 





Figure 1-3 The Cryo-EM maps of class I to IV particles when 
DENV2 strain New Guinea C (NGC) sample was incubated at 37°C. 
The surfaces of the maps (above) and the central cross-sections (below) 
are colored radically (shown in the lower panel). The white triangle 
represents an icosahedral asymmetric unit, and the corresponding 2-, 
3-, and 5-fold symmetry vertices are indicated (Figure extracted from 
(Fibriansah et al., 2013)). 
1.5 Structure of proteins  
The dengue virus genome is translated to one polypeptide which is 
subsequently processed into 3 structural (E, prM, C) and 7 
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) by 
several host and viral proteases (Fig. 1-4) (Lindenbach and Rice, 2003). 
Structural proteins are the building blocks of the virus particle, while 
non-structural proteins mainly help the transcription, translation of the 
viral genome and post-translational modifications of the viral proteins. 





Figure 1-4 The known protein structures for dengue virus. From left 
to right: Capsid protein, PDB code 1R6R; prM protein (prM part of 
prM-E chimera), 3C6E; Envelope protein, 1OAN; NS1, 4O6B; 
NS2B-NS3 protease, 2FOM; NS3, 2VBC; NS5, 4VOQ. 
1.5.1 Capsid protein  
Capsid protein is a highly basic protein with a molecular weight of 
12 kDa. The C-terminal hydrophobic signal peptide is removed by the 
NS2B-NS3 protease (Amberg et al., 1994, Yamshchikov and Compans, 
1995). The RNA genome forms a complex with capsid proteins, which is 
encapsulated by the virus bilayer lipid membrane. Crystal and NMR 
structures of the capsid protein showed that it exist as dimers in solution 
(Jones et al., 2003, Ma et al., 2004). A capsid protomer consists of four 
helices: α1, α2 and α3 which form a three-helix core and a long α4 
extending outwards. The capsid structure is stabilized by a large 




and α4-α4’ helix pairs. The charge distribution on its surface is 
asymmetric with a hydrophobic patch at the exposed surface of the 
α2-α2’ interface and a positive charge patch at the solvent-exposed 
edge of α4-α4’. The hydrophobic patch is assumed to interact with the 
lipid bilayer (Markoff et al., 1997), while the positive charge side is 
proposed to interact with the negatively-charged RNA genome (Wang 
et al., 2002, Ma et al., 2004).  
1.5.2 The prM protein 
The prM protein acts like a chaperone for envelope protein folding. 
It is cleaved by host protease furin to M and pr molecules when the 
immature virus is exposed to the low pH environment of the TGN 
(Stadler et al., 1997). The M part contains an ectodomain of about 20 
amino acids, a stem region and two transmembrane helices (Zhang et 
al., 2003). In the mature virus surface, the M protein lies below the E 
protein shell (Zhang et al., 2003). 
1.5.3 The E protein  
The E protein has an elongated shape and a molecular weight of 
about 54 kDa. This multifunctional protein participates in receptor 
binding and membrane fusion processes (Rey et al., 1995). An E 




stem region connecting these two domains (Fig. 1-5a). E protein 
ectodomain is further divided into three domains, domain I, II and III 
(Rey et al., 1995, Modis et al., 2003) (Fig. 1-5b). Domain I forms a 
β-barrel with eight β-strands and domain II has an elongated shape with 
the conserved hydrophobic fusion loop at its distal end. Domain I-II 
hinge facilitate the flipping of domain II so as to expose the fusion loop 
(Modis et al., 2004, Bressanelli et al., 2004). Domain III, which has an 
immunoglobulin fold, contains seven β-strands forming two β-sheets 
facing each other. The DI-III hinge facilitates the changes of position of 
DIII relative to DI as observed in the post-fusion E protein structure 
when exposed to low pH. E protein is glycosylated at one or two 
residues, depending on the cell line in which the virus is propagated 
(Lee et al., 1997). One of the glycosylated residue, N67, is 
demonstrated to be involved in the binding to the receptor DC-SIGN on 
dendritic cells (Mukhopadhyay et al., 2006). In low pH environment and 
with presence of liposomes, E proteins form the post-fusion trimeric 
structure, (Modis et al., 2004, Bressanelli et al., 2004) (Fig. 1-5c). In this 
structure, E protein domains undergo major rearrangements: domain II 
rotates ~30o relative to domain I about the DI-II hinges, while domain III 




formation of the packing interfaces and increased buried surface area of 
each monomer in the trimer compared to that in the dimer. The fusion 
loops are assembled at the tip of the trimer (Fig. 1-5c). 
 
Figure 1-5 The Envelope protein of dengue virus.  
(a) Cryo-EM structure of E protein and the M protein on mature virus 
(PDB code 3J27). E protein stem and transmembrane (TM) regions are 
colored as cyan. M protein stem and transmembrane (TM) regions are 
colored as magenta. (b) Crystal structure of dimeric E proteins at 
neutral pH (PDB code 1OAN), with DI-III linker and DI-II hinge 
highlighted. (c) Crystal structure of trimeric post-fusion E protein at low 
pH (PDB code 1OK8). Domain I, II and III of one of the E proteins are 
colored in red, yellow and blue, respectively. The fusion loop is colored 
in green. Symmetry-related E proteins in (b) and (c) are colored in grey.  
1.5.4 Non-structural proteins 
All non-structural proteins are involved in the formation of the 
replication machinery. They are assembled mostly on the cytoplasmic 




(Muller and Young, 2013). In the replication complex, the NS3 and NS5 
function on a scaffold form by the other four non-structural proteins (Fig. 
1-6). 
 
Figure 1-6 Hypothetical model of the dengue virus replication 
complex. The replication complex resides inside the membranous 
vesicle packets in infected cells. All seven non-structural proteins 
together with some host factors, forming the replication complex. This 
figure is adopted from (Muller and Young, 2013). 
1.5.4.1 NS1 
NS1 protein has three domains and its molecular weight that ranges 
between 46-55 kDa is dependent on the degree of glycosylation at three 
glycosylation sites: N130, N175 and N207 (Akey et al., 2014). NS1 
glycoprotein exists in three different forms in infected cells: the 
intracellular dimeric form at the site of the viral replication complex on 




involved in signal transduction, and the secreted hexameric form that 
interacts with components of the complement-mediated immune system 
(Muller and Young, 2013). NS1 is essential for the replication of the 
flavivirus genome (Mackenzie et al., 1996, Lindenbach and Rice, 1997, 
Lindenbach and Rice, 1999), and involved in immune system evasion 
and pathogenesis (Chung et al., 2006, Avirutnan et al., 2010). 
Full-length NS1 protein has been crystallized as a hexamer (Akey et al., 
2014), and is consistent with the electron microscopy structures 
(Gutsche et al., 2011, Muller and Young, 2013). NS1 hexamer forms an 
open-barrel protein shell with lipids in its central channel, which has 
been proposed a role in hijacking lipid metabolic pathways to result in 
endothelium dysfunction (Gutsche et al., 2011). It has also been 
postulated that cross-reactivity of anti-DENV NS1 antibodies to host 
proteins and endothelial cells can cause autoimmune reaction and 
endothelium dysfunction (Lin et al., 2003, Lin et al., 2005). NS1 is also a 
major target of the humoral immunity (Dejnirattisai et al., 2010, 
Beltramello et al., 2010). 
1.5.4.2 NS3 




viral replication. The NS3 N-terminal domain together with the 40 
residues long segment of NS2B serves as a serine protease, 
responsible for the cleavage of the viral polyprotein (Lindenbach and 
Rice, 2001, Bera et al., 2007). The C-terminal domain of NS3 is an 
ATPase/helicase can provide energy for the helicase domain to 
untangle the viral RNA for amplification (Li et al., 1999). Also, 
NS3-NS2A complex has been proposed to play a role in virus assembly 
(Patkar and Kuhn, 2008). 
1.5.4.3 NS5 
NS5 is a multifunctional enzyme that comprises of 900 amino acid 
residues. Its N-terminal portion contains an S-adenosyl-L-methioinine 
(SAM)-dependent methyltransferase (MTase) domain, which caps the 
viral RNA genome for stability and facilitates translation (Egloff et al., 
2002). Methylations of the Guanine N-7 atoms and ribose 2’-OH also 
help evade the host innate immune response (Ray et al., 2006, Zhou et 
al., 2007). Residues 273-900 at the C-terminus end of NS5, is the 
RNA-dependent RNA polymerase (RdRp), which synthesizes the viral 
genome (Yap et al., 2007). NS5 can also antagonize the host interferon 




1.5.4.4 NS2A, 2B, 4A, 4B 
NS2A, NS4A and NS4B are small hydrophobic proteins with 
multiple transmembrane regions embedded in the ER membrane (Miller 
et al., 2006, Miller et al., 2007, Xie et al., 2013, Xie et al., 2014). NS2A 
participates in RNA synthesis and virion assembly/maturation (Xie et al., 
2013). NS4A and NS4B co-localize with other DENV proteins and 
dsRNA, suggesting they may form part of the membrane-bound viral 
replication complex (Miller et al., 2007, Miller et al., 2006). They are 
thought to anchor other components of the replication complex to the 
cytoplasmic site of ER-derived membrane. For example, NS4B has 
been found to directly interact with NS1 (Youn et al., 2012) while NS2B 
mainly act as a cofactor of NS3 protease (Lindenbach and Rice, 2003). 
In addition, NS2A and NS4A are capable of blocking IFN-mediated 
signal transduction (Muñoz-Jordán et al., 2003, Muñoz-Jordán et al., 
2005).  
1.6 Life cycle of dengue virus 
DENV has been shown to be able to infect various human cell types: 
dendritic cells, monocytes, macrophages, B cells, T cells, endothelial 




which can be used for viral propagation (Anderson, 2003). From clinical 
and autopsy studies, dendritic cells, monocytes and macrophages are 
found to be the primary targets for DENV infection in vivo (Jessie et al., 
2004, Durbin et al., 2008).  
It is hypothesized that during entry into the cell, the domain III of the 
E protein of DENV bind to a receptor (Crill and Roehrig, 2001, Rey et al., 
1995). Several mammalian cell receptors or attachment factors have 
been identified, suggesting that DENV might be able to enter cells using 
more than one molecule. The identified receptors or attachment factors 
include heparan sulfate (Chen et al., 1997, Liu and Thorp, 2002), heat 
shock protein 70 and 90 (Reyes-del Valle et al., 2005), GRP78/BiP 
(Jindadamrongwech et al., 2004), CD14 (Chen et al., 1999), laminin 
receptor (Thepparit and Smith, 2004), mannose receptor (Miller et al., 
2008) as well as DC-specific intercellular adhesion molecule 3 grabbing 
non-integrin (DC-SIGN) (Tassaneetrithep et al., 2003, Lozach et al., 
2005, Navarro‐Sanchez et al., 2003). These receptors demonstrate 
different affinities and interactions to DENV. For example, DC-SIGN 
interacts with the virus via carbohydrate moieties on E protein 
(Pokidysheva et al., 2006). DENV can also interact with a C-type lectin 




proinflammatory cytokines (Chen et al., 2008).  
Upon virus attachment to receptor, clathrin-mediated endocytosis 
ensues (van der Schaar et al., 2007). The virus is subsequently 
transported from the early endosomes to the late endosomes (van der 
Schaar et al., 2008), where the low pH environment and the anionic 
lipids of the endosomes induce the rearrangement of the virus surface 
proteins (Zaitseva et al., 2010). The E proteins rearrange from dimers to 
trimers and the fusion loop is inserted into the host-cell membrane. The 
movement of domain III relative to domain I/II folds the C-terminus of E 
protein towards the fusion loop, which bends the membranes to form a 
lipid fusion pore (Modis et al., 2004, Bressanelli et al., 2004). The viral 
genomic RNA is released into the cytoplasm and translated into 
polyprotein, which is then processed to form structural and 
non-structural proteins. As described in section 1.5.4, the non-structural 
proteins form replication complex, which initiates replication of the viral 
genome (Lindenbach and Rice, 2003). The newly synthesized RNA 
genome and structural proteins are assembled into immature virus and 
the virus is then transported through the TGN where the prM protein 
gets cleaved by the host protease furin. The pr peptide only falls off 




neutral pH environment (Stadler et al., 1997, Yu et al., 2008). This 
completes the maturation process. 
 
Figure 1-7 Life cycle of dengue virus.  
(a) Virions enter the cell via receptor-mediated endocytosis. (b) In the 
endosome at acidic pH, E protein facilitates the fusion between virus 
and endosomal membranes, releasing the virus genome into the 
cytoplasm. (c) Viral RNA is translated. (d) Viral genomic RNA is 
replicated. (e) Immature virus particles are assembled at the ER 
membrane. (f) prM is cleaved by furin in TGN. (g) Mature virus is 
released into the extracellular environment, and the pr domain falls off 
the virus completing the maturation process. The numbers in colored 
boxes refer to the pH values in the respective compartments. Figure 
extracted from (Rodenhuis-Zybert et al., 2011). 
1.7 Human immune response to dengue infection  
Recovery from a dengue infection by one serotype provides lifelong 




is only partial and temporary (Halstead, 1988). More importantly, 
subsequent infection with a second serotype, can result in the 
development of dengue hemorrhagic fever (Rothman, 2004, Halstead 
and O'Rourke, 1977a). 
1.7.1 Cellular immune responses to dengue infection 
The role of cellular response in dengue protection is complex. T 
cells recognize viral antigen presented by the MHC molecules in 
infected cell instead of intact virion and the main target of T cell 
response during a natural dengue infection has been found to be NS3 
and NS5 (Rivino et al., 2012, Duangchinda et al., 2010). After 
recognizing virus-infected cells, T cells respond to DENV infection with 
diverse effector functions: proliferation of T cells, lysis of infected-cells 
and production of cytokines (Rothman, 2011). The cytokines produced 
include interferon-γ (IFNγ), tumour necrosis factor (TNF) and 
interleukin-2 (IL-2) (Rothman, 2011). IFNγ produced by stimulated 
CD4+ T cells was shown to be able to augment DENV infection in vitro 
in cooperation with antibody-virus immune complex (Kurane et al., 
1989). This can be explained by a theory called “the original antigenic 
sin”, in which the cellular immune response is skewed to primary 




secondary infection (Mongkolsapaya et al., 2003). The cross-reactive 
DENV-specific T cells offer suboptimal degranulation and high cytokine 
production, which contributes to the development of vascular leakage 
(Duangchinda et al., 2010). Inhibition of the central cytokine regulator 
CLEC5A was able to rescue mice from vascular permeability in a 
DHF/DSS mouse model (Chen et al., 2008). However, recent findings 
have presented a controversial view that pre-existing DENV-specific T 
cells are protective (Weiskopf et al., 2013, Dung et al., 2010). 
Additionally, it is important to note that the original antigenic sin alone 
cannot be the only risk factor for severe dengue disease, because 
infants, who do not have a pre-existing T cell memory, can also suffer 
from severe dengue (Kliks et al., 1988). 
1.7.2 Humoral immune response to dengue infection  
Antibody plays a key role in long-term protection against dengue 
(Sabin, 1952). This is supported by vaccine studies using inactivated 
Japanese encephalitis virus and yellow fever virus (Monath et al., 2002, 
Hoke et al., 1988). In a primary DENV infection, immunoglobulin M (IgM) 
antibodies are the first to be generated, peak at ~2 weeks following 
fever onset and subsequently decrease to undetectable levels over the 




be detectable at low titer at the end of the first week of illness (Guzman 
et al., 2010) (Fig. 1-8). In contrast, during a secondary infection, high 
levels of IgG antibodies which are cross-reactive to many flaviviruses 
are already detectable even during the acute phase (Innis et al., 1989). 
 
Figure 1-8 Antibody responses in primary dengue infection.  
After dengue infection, NS1 can be first detected as well as viraemia. 
As viraemia wanes, IgM antibodies are first produced followed by IgG 
antibodies produced at the later stage. Figure adapted from (Guzman et 
al., 2010). 
 
Antibodies against DENV can be protective but at lower 
concentrations, it can become detrimental to the patient due to a 
mechanism called antibody-dependent enhancement (ADE). One 
strong evidence for ADE is that maternal antibodies can induce DHF in 
newborn baby (Kliks et al., 1988). This phenomenon can also be 




O'Rourke, 1977a) and in vivo with animal models (Goncalvez et al., 
2007, Zellweger et al., 2010). In this phenomenon, non-neutralizing 
antibodies, or neutralizing antibodies at sub-neutralizing concentration, 
were shown to ligate Fc-γ receptors on monocytes or macrophages to 
suppress innate immunity (Chan et al., 2011, Balsitis et al., 2010).  
Serotype-specific DENV antibodies bind to only one serotype; 
DENV complex reactive antibodies cross-react with different serotypes. 
Most of the IgG antibodies generated from natural infection are 
cross-reactive and weakly neutralizing and only a small subset of them 
is serotype-specific and highly neutralizing (Beltramello et al., 2010, de 
Alwis et al., 2011, Dejnirattisai et al., 2010). These antibodies react with 
E, prM and NS1. Antibodies targeting NS1 can be protective. They can 
stimulate complement-mediated lysis of infected cells or Fc-γ 
receptor-mediated phagocytosis following antibody recognition of cell 
surface-bound NS1 (Muller and Young, 2013). Due to molecular 
mimicry, NS1 can also elicit antibodies, which cross-react with host cell 
components, such as platelets and components of extracellular matrix. 
This could cause damage to the endothelial cells. Antibodies targeting 
prM are mostly cross-reactive, non-neutralizing and ADE-promoting 




targeting E proteins are protective and produced at a level sufficient for 
neutralization of all DENV serotypes during early convalescence 
following acute infection (Sabin, 1952). However, as antibody levels 
decline, only serotype-specific antibodies remains neutralizing and are 
able to protect the host from re-infection. Serotype-specific antibodies 
have hence been suggested to play a key role in the life-long protection 
against dengue infection.  
An ideal therapeutic antibody should render strong neutralization 
while at the same time minimize or even eliminate enhancement across 
serotypes. Neutralization is defined here as the abolition of virus 
infection without a need for leukocytes (except production of the 
antibody). There are two strategies to develop an antibody therapy for 
DENV infection. One of which is to generate cross-reactive antibodies 
that can bind to and neutralize all four serotypes of dengue virus. This 
requires the identification of antibodies that bind to functional epitopes 
conserved between all four serotypes. The other strategy is to generate 
highly neutralizing serotype-specific antibodies, and combine antibodies 
each specific to a serotype into a cocktail.  
1.7.3 Neutralization of dengue virus by monoclonal antibodies  




extensively studied. They are mainly mapped to E protein domain III 
(E-DIII), including lateral ridge and A-strand (Crill and Roehrig, 2001, 
Sukupolvi-Petty et al., 2007, Nybakken et al., 2005, Lok et al., 2008, 
Cockburn et al., 2012a) (Fig. 1-9a). However, a previous study has also 
showed that the E-DIII lateral ridge antibody was detected at low levels 
and did not correlate with clinical outcomes (Oliphant et al., 2007). It 
has also been found that one highly neutralizing chimpanzee antibody 
bound to E-DI and the same epitope region was demonstrated to be 
immunogenic in humans by the same study (Cockburn et al., 2012b) 
(Fig. 1-9b). 
With the recent technological developments in isolating human 
monoclonal antibodies (MAbs) from memory B cells and plasmablasts, 
neutralizing epitopes recognized by human monoclonal antibodies can 
be characterized. Although some of the neutralizing antibodies from 
humans are still mapped to E-DIII A-strand (Beltramello et al., 2010), 
anti-DIII antibodies have been shown to form only a small fraction in the 
repertoire of human antibodies. This is consistent with another study 
showing that human serum depleted of E-DIII targeting antibodies 
remained highly neutralizing against dengue virus (Crill et al., 2009, 




neutralizing antibodies, human serotype-specific neutralizing antibodies 
target quaternary structure-dependent epitopes present only on intact 
compact mature dengue virus (de Alwis et al., 2012, Teoh et al., 2012, 
Kaufmann et al., 2010, Fibriansah et al., 2014, Fibriansah et al., 2015b) 
(Fig. 1-9d). Also, a new class of epitope that is recently identified is the 
E protein dimer epitope (Fig. 1-9c). Antibodies targeting this class of 
epitopes can be either cross-reactive or serotype-specific (Fibriansah et 
al., 2015a, Dejnirattisai et al., 2015, Rouvinski et al., 2015). However, 
the majority of antibodies in the human serum are cross-reactive and 
poorly neutralizing and they target either prM protein or E-DI/II, 
especially the fusion loop region (Dejnirattisai et al., 2010, Beltramello 
et al., 2010, de Alwis et al., 2011, Lai et al., 2008, Smith et al., 2012). 
Although antibodies targeting the fusion loop or adjacent regions 
isolated from patients from primary infection are generally poorly 
neutralizing, its neutralization capacity seemed to improve in patients in 




Figure 1-9 Major neutralizing epitopes of DENV antibodies. Highly 
neutralizing epitopes are classified as anti E-DIII lateral ridge and 
A-strand (a), E-DI (b), envelope dimer epitope (EDE) (c), and 
quaternary structure-dependent antibodies (d). The epitope is 
highlighted with a circle of the same color as the dot near the name of a 
typical antibody from that class. In (b), the antibody 1F4 binds to E-DI 
and DI/II hinge with its footprint restrained to E protein monomer. But it 
only recognizes the E protein on the virus surface with the correct hinge 
angle, thus it can also be considered as a quaternary 
structure-dependent antibody. 
 
The potency of antibodies can partially be determined by its affinity 
to the epitope and also the accessibility of the epitope on the virus 
particle (Pierson et al., 2007). Antibody affinity, defined as the strength 
of the antibody-antigen interaction, has been found to correlate with 




antibody to various virus strains or genotypes can result in the reduction 
of its neutralization potency (Sukupolvi-Petty et al., 2010, Wahala et al., 
2010). However, differences in antibody neutralizing capabilities against 
different virus strains cannot always be fully explained by the variation 
of antibody affinity alone (Shrestha et al., 2010, Austin et al., 2012).  
Epitope accessibility, defined as the number of epitopes accessible 
for binding on the virion, has therefore been suggested to explain for 
this discrepancy. The number of antibodies which was required to 
neutralize a virion was suggested to be determined by the accessibility 
of the particular epitope (Pierson et al., 2007). For a more potent MAb, a 
lower fraction of all accessible epitope sites was required to be bound 
for neutralization. In addition, weakly neutralizing MAbs with less 
accessible epitope sites on the virus surface were suggested to require 
almost complete occupancy. Antibody needs to achieve a critical 
number of occupancy for neutralization, lower occupancy than that was 
thought to result in the enhancement of infection in cells bearing Fc-γ 
receptors. For instance, the occupancy on the virus particle in order to 
neutralize WNV, a closely related flavivirus, was suggested to be 30 out 
of 180 copies of its surface E proteins. Epitope accessibility can be 




within a protein or by the neighboring E proteins on the virus structure, 
(2) the different E protein arrangement due to various virus maturation 
state, and (3) the dynamics of virus structure (Dowd and Pierson, 2011, 
Lee et al., 2013, Dowd et al., 2014). For example, the epitope of 
cross-reactive non-neutralizing murine antibody, 2H12, was found to be 
centered on the E-DIII AB loop, which was blocked by steric obstruction 
by the fusion loop from the opposing E protein molecule in the E dimeric 
structure (Midgley et al., 2012). Another antibody E53, was shown to be 
unable to bind to mature virus since its epitope, the fusion loop, is 
hidden in this conformation. It however, binds to E proteins in the 
immature virions as the epitope is exposed (Cherrier et al., 2009). 
Recent findings showing that the mature DENV2 can undergo structural 
changes when incubated at human physiological temperatures 
(Fibriansah et al., 2013, Zhang et al., 2013) and therefore can alter 
epitope accessibility.  
Anti-DIII antibodies can neutralize DENV by inhibiting attachment 
(Crill and Roehrig, 2001) or  the fusion process (Thompson et al., 
2009). Binding of antibodies to E-DIII was also suggested to trap virus 
at its transition fusion structure (Kaufmann, 2006). On the other hand, 




cross-link virus surface preventing E protein rearrangement required for 
different stages of entry into cells, such as attachment or fusion 
(Fibriansah et al., 2014, Teoh et al., 2012). Lastly, another class of 
antibodies that bind to partially hidden epitopes, such as murine 
antibody 1A1D-2, neutralizes virus by disrupting the virus surface 
structure (Lok et al., 2008). While various neutralization mechanisms 
have been identified, there are still many unknowns, as such, a 
complete understanding of DENV - human antibody interaction would 
provide important information for vaccine and therapeutics 
development.  
1.8 Dengue vaccine  
The development strategy for dengue vaccine can be generally 
categorized into four types, each with its own advantages and 
drawbacks. The four types of vaccines are inactivated virus, live 
attenuated virus, recombinant protein vaccine and DNA vaccine. 
Successful vaccines had been developed for other flavivirus such as, 
the yellow fever virus (YFV), Japanese encephalitis virus (JEV), and 
tick-borne encephalitis virus (TBEV). Among them are the YF17D (for 




inactivated TBEV vaccine. There is also an inactivated virus vaccine for 
JEV. Significant progress has been made in the development of 
tetravalent DENV vaccine. There is currently one vaccine candidate in 
phase III clinical trials, and others at earlier stages of clinical 
development (Thomas, 2014).  
1.8.1 Inactivated virus vaccine  
The inactivated virus vaccine does not replicate in patients and is 
therefore likely to be safe. However, the immune response elicited is 
generally weaker than when live attenuated vaccine is used. Some 
candidate inactivated DENV vaccine has been developed and the result 
shows that it can induce highly neutralizing antibody response that 
protects against viraemia in a primate model (Putnak et al., 1996).  
1.8.2 Live attenuated virus vaccine  
Live attenuated vaccine contains virus with reduced replication 
capability, so that it will not cause disease, but is able to elicit adaptive 
immune responses. Live-attenuated vaccines can be generated by two 
strategies, either by continuous passaging of the virus in tissue culture, 
or constructing mutant virus with its RNA backbone modified.  
A tetravalent live attenuated vaccines, ChimeriVax from Sanofi 




consists of DENV prM and E structural genes inserted into the yellow 
fever vaccine (YF17D) backbone (Guirakhoo et al., 2001). The safety of 
this vaccine has been proven in phase I trial, which also showed 
relatively low viraemia in vaccinated individuals (Capeding et al., 2011). 
Phase II trial of this vaccine confirmed its safety but showed varied 
efficacy against different serotypes, with essentially no protection 
against DENV2, leading to an average efficacy of only 30.2% 
(Sabchareon et al., 2012). Phase III trial of this vaccine in Asia showed 
that it could reduce the incidence of symptomatic infection and hospital 
admission with a efficacy of 56.5%, However, the efficacy against 
DENV2 was lower, consistent with the observations in phase II trial 
(Capeding et al., 2014). The vaccine trials showed vaccinated 
volunteers above the age of 9 did not have disease enhancement after 
natural infection with dengue and also hospitalization is reduced 
(Hadinegoro et al., 2015). However, vaccinated children below the age 
of 9 year showed increased hospitalization. 
In another case, attenuated DENV vaccine candidate developed by 
Mahidol University had not been successful due to adverse side effects 
observed in the phase I and II clinical trials (Kanesa-Thasan et al., 2001, 




produced by passaging the different DENV serotypes multiple times in 
either primary dog kidney cells or primary African green monkey kidney 
cells and combining them into a tetravalent formulation 
(Bhamarapravati and Sutee, 2000).  
Similarly, a tetravalent vaccine developed by the Walter Reed Army 
Research Institute (WRAIR) was produced by passaging all dengue 
virus serotypes in primary dog kidney cell (PDK-53) and then a final 
passage in fetal rhesus lung cell (Butrapet et al., 2000). This vaccine 
induced differing immunogenicity and reactogenicity towards the four 
different serotypes (Sun et al., 2003, Edelman et al., 2003, Sun et al., 
2009). In this vaccine, DENV1, DENV3 and DENV4 were not 
attenuated enough to prevent development of disease. The PDK-53 
vaccine strain of DENV2 was then used as a backbone to engineer 
chimeric vaccine whereby its structural protein genes were swapped 
with those from DENV1, 3 or 4. This formulation was named DENVax 
(Huang et al., 2003). Phase I trial of this vaccine showed low side 
effects and can induce immunogenicity in healthy, flavivirus-naive 
adults (Osorio et al., 2014). However, further clinical trials in different 
age groups and in dengue-endemic areas are needed. 




an attenuation strategy. DENV1 and DENV4 with their 30-nucleotide 
deleted (Δ30) in the 3’-UTR, retained their immunogenicity (designated 
DEN1Δ30 and DEN4Δ30) (Men et al., 1996, Whitehead et al., 2003). 
The DEN4Δ30 was then used as a backbone to engineer chimeric 
DENV2 and DENV3 vaccines. Various tetravalent mixtures are 
currently being tested in Phase I clinical trial (Kirkpatrick et al., 2015, 
Durbin et al., 2013). After vaccination, the characteristics of HMAbs 
derived from memory B cells were similar to those generated in a 
natural infection (Smith et al., 2013). 
1.8.3 Recombinant protein vaccine 
Similar to inactivated vaccine, recombinant E protein vaccine is 
expected to have a better safety profile. Induction of an equally 
protective immune response against the different serotypes can also be 
controlled by differing dosage of E proteins from each serotype. 
However, since the protein is small in size, addition of adjuvants and 
multiple injections are required to stimulate immune response. E protein 
constructs, developed by Hawaii Biotech (later acquired by Merck & Co), 
contain prM and 80% of E protein. These recombinant proteins are 
expressed with Drosophila melanogaster Schneider 2 (S2) cells in their 




vaccine is currently undergoing phase I clinical trial. There are also 
other dengue protein constructs developed to be vaccine candidates. 
The domain III of E protein as a fusion protein (Hermida et al., 2006, 
Bernardo et al., 2008, Leng et al., 2009), or E-DIII plus capsid (Zuest et 
al., 2015), have been developed and served as proof-of-concept that a 
fragment of the DENV structural proteins can induce protective 
immunity in various animal models.  
1.8.4 DNA vaccine 
DNA constructs can also be used as vaccines. Peptides of antigens 
are expressed after these DNA constructs are introduced into cells. 
Compared to conventional vaccines, its advantages include ease of 
production, better stability at room temperature and the possibility to 
vaccinate against several pathogens in a single vaccination (Beckett et 
al., 2011). Nevertheless, adjuvants, multiple doses and specialized 
injection equipment are needed (Thomas, 2014). Although protection 
has been shown in non-human primate model (Raviprakash et al., 
2003), a recent clinical phase I trial with a DENV1 DNA construct 
(encoding prM and E proteins) given in three doses shows induction of 





Table 1-1 Dengue vaccines under development. 
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1.9 Aim of the project 
Recent dengue vaccine phase II and III trials by Sanofi Pastuer 
showed no protection against DENV2. DENV2 particles have been 
observed to change in structure when shifting from an incubation 
temperature of 28oC to 37oC. To aid in the rational design of effective 
antiviral therapeutics and vaccines, it is necessary to understand the 
neutralization of different morphologies of DENV2 by human 
neutralizing antibodies at molecular level.  
The specific aims of this thesis are to 
1. Characterize epitopes recognized by DENV2-specific highly 
neutralizing human monoclonal antibodies. 
2. Investigate the impact of structural dynamics of DENV2 on 
antibody-mediated neutralization.  
3. Provide a structural basis for understanding the mechanisms of 








Chapter II. Materials and Methods  
2.1 Antigen production and purification  
2.1.1 Recombinant E protein ectodomain cloning, expression and 
purification  
Recombinant E protein soluble ectodomain construct was based on 
DENV2 strain 16681. In general, the virus RNA genome was extracted 
using QIAamp viral RNA mini kit (Qiagen) and the gene encoding E 
protein ectodomain (amino acid 1-394) was reverse transcribed to 
cDNA using the cDNA synthesis kit (Life Technologies). The product 
was amplified and flanked by sequences of BgI II and Xho I restriction 
sites by PCR. This PCR product was then ligated to pMT/BiP/V5-His A 
vector. The resulting plasmid and a hygromycin resistant plasmid (Life 
Technologies) were used to co-transfect Drosophila Schneider 2 cells. 
The cells were subsequently cultured and selected to generate a stable 
cell line. Protein expression was induced with CuSO4 at a final 
concentration of 500 μM at a minimum cell concentration of 1X106 cells 
per ml for 6 days. Upon which, the culture supernatant was harvested 
by centrifugation and filtered prior to purification with a homemade 
affinity column. Briefly, DENV cross-reactive monoclonal antibody IgG 




using AminoLink Immobilization Kit (Thermo Scientific ) and the beads 
were then packed into a low-pressure Glass Econo chromatography 
column (Bio-Rad). The filtered supernatant was allowed to flow through 
the column by a gravity-flow method and non-specific binders were 
washed away from the column. The protein was finally eluted with a low 
pH elution buffer (0.1 M glycine-HCl, pH 2.7) and the pH was instantly 
adjusted to neutral using 1 M Tris-HCl buffer, pH 9.0. The eluted protein 
was further dialyzed in 10 mM Tris-HCl pH 7.5 and 150 mM NaCl, and 
then further purified by size-exclusion chromatography using a 
Superdex 200 10/300 GL column (GE Healthcare). 
2.1.2 E protein domain III cloning, expression, refolding and 
purification  
Residues 291-395 of DENV2 E protein (strain PVP94/07) were 
cloned into pET16b vector (Novagen) fused with an N-terminal 10X 
Histidine tag (Moreland et al., 2012). To generate the E-DIII construct 
representing strain NGC, residue 390 was mutated from serine to 
asparagine by site-directed mutagenesis with primers (forward: 
5’-GGACAACTGAAGCTCAACTGGTTTAAGAAAGG-3’, and reverse: 
5’-CCTTTCTTAAACCAGTTGAGCTTCAGTTGTCC -3’) using 




To facilitate protein crystallization, four flexible N-terminal residues 
(291-294) of this E-DIII construct were removed and only residues 
295-395 were amplified with primers (forward, 
5’-CTGTATTTTCAGGGCGCCGGCAAAGGAATGTCATATTCTATGTG
TACAGG-3’, and reverse, 5’-GCGACTAGTGAGCTCGTCGACTTATCC 
TTTCTTAAACCAGCTGAG-3’) and cloned into pProEx HTb plasmid 
using ligation-independent cloning methods (Aslanidis and de Jong, 
1990). The expressed construct includes a 6X His-tag and a Tobacco 
Etch Virus (TEV) protease cleavage site fused at the N-terminus of this 
construct. 
The recombinant E-DIII constructs were transformed to Escherichia. 
coli BL21-CodonPlus strain (Stratagene) and the bacteria were grown in 
LB medium containing 34 μg/ml chloramphenicol at 37oC to an 
absorbance of 0.6-0.8 at 600 nm wavelength. Protein expression was 
induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 
37oC in a shaker for 4 hrs. Cells were harvested by centrifugation at 
8000g for 30 min at 4oC. Bacteria containing over-expressed proteins 
were passed through a French cell press twice (Thermo Electron Corp) 
pre-cooled to 4°C. E-DIII was detected in the inclusion body fraction as 




clarified with washing buffer (0.1M Tris-HCl pH 8.5, 200 mM NaCl, 1 M 
Urea, 20% Triton X-100) for three times and re-pelleted each time by 
centrifugation. The inclusion body was then dissolved in 0.1 M Tris-HCl 
pH 8.5, 200 mM NaCl, 8 M Urea, 10 mM imidazole, 10 mM 
β-mercaptoethanol (buffer A) overnight at 4oC and loaded into a 
HisTrap FF Crude column in AKTA protein purification systems (GE 
Healthcare). After a washing step with 20 mM imidazole, the protein 
was eluted with an imidazole gradient (0 – 500 mM) in buffer A and 
refolded by dialysis with refolding buffer (0.2 M Tris-HCl pH 8.5, 200 
mM NaCl, 100 mM arginine, 10 mM EDTA, 5 mM reduced glutathione, 
0.5 mM oxidized glutathione) (Moreland et al., 2012). The refolded 
protein was further purified over a Superdex 75 16/60 size exclusion 
column (GE Healthcare) equilibrated in 20 mM Tris-HCl pH 7.5, 150mM 
NaCl. Recombinant E-DIII for crystallization was cleaved by TEV 
protease overnight at 4°C and the product was purified by passing 
through HisTrap FF Crude column (GE Healthcare).  
2.1.3 Virus sample preparation  
DENV2 strains NGC and PVP94/07 were used in this study. Strain 
PVP94/07 (DEN2/SG/07K3598DK2/2007) was obtained from the EDEN 




Professor Ooi Eng Eong. All viruses were grown in C6/36 mosquito 
cells at 28°C and the virus used in cryo-EM and dynamic light scattering 
study was purified as described (Kuhn et al., 2002). Briefly, C6/36 cells 
was grown with RPMI 1640 medium (HyClone) containing 10% FCS at 
28°C. Cells were infected at a MOI of 0.1, and culture medium was 
harvested 96 hrs post-infection. To purify the virus, the culture medium 
was clarified by centrifugation at 6000g for 30 min, and the supernatant 
was precipitated by incubating overnight at 4°C with 8% PEG 8000 
(Sigma-Aldrich). The mixture was centrifuged at 7000g, and the pellet 
was resuspended in NTE buffer (12 mM Tris pH 8.0, 120 mM NaCl, 1 
mM EDTA). The virus was then purified through a 24% sucrose cushion 
and a 10 to 30% potassium tartrate-glycerol linear gradient. The virus 
band was extracted and subjected to buffer-exchange into NTE buffer, 
and concentrated in an Amicon Ultra-4 concentrator (100 kDa; Millipore). 
The purity of the virus sample was evaluated by SDS-PAGE (Fig. 2-1). 
Purified virus sample showed very faint pre-membrane (prM) protein 
band, corresponding to lower percentage of immature particles in the 
sample. The virus concentration was estimated by comparing the viral E 
protein band with a bovine serum albumin (BSA) protein standard of 





Figure 2-1 SDS-PAGE gel of the purified DENV2 strain PVP94/07. 
Lane A: Protein standard; B: virus sample; C-F: BSA protein 
concentration standard at 2, 1.5, 1, 0.5 mg/ml, respectively. Virus 
protein bands corresponding to E, prM, capsid and M proteins are 
labeled.  
2.2 Antibody IgG and antigen binding fragment (Fab) generation  
Both HMAb 10.15 (Teo, 2014) and 3F9 (Smith et al., 2014) were 
isolated from B cells of convalescent dengue patients using two 
different methods. For generation of 3F9, human B cells from a dengue 
patient were transformed with Epstein-Barr virus (EBV) and screened 
for virus specificity in ELISA and neutralizing activity in a flow-cytometry 
based assay. Selected cells were cryofused with myeloma cells to 
generate hybridomas (Smith et al., 2014). For generation of HMAb 
10.15, genes of both antibody heavy and light chains were amplified 
from B cells, which were isolated from a convalescent patient, and 




was expressed on phage surface and panned for DENV2 binding 
specificity. Constructs with desired specificity were further cloned and 
expressed as full-length IgG monoclonal antibodies. Both antibodies 
were proven to be extremely potent against DENV2 in vitro.  
To obtain Fab used for crystallization and cryo-EM study, IgG of 
HMAb 10.15 (IgG 10.15) and 3F9 (IgG 3F9) were digested by 
immobilized papain resin (Pierce) for 22 and 18 hrs in a 37oC shaker, 
respectively. The digestion time was pre-optimized to obtain a high yield 
of Fab and avoid over-digestion. Digested antibodies were separated 
from the resin and the supernatant was dialyzed against 10 mM 
Tris-HCl pH 7.5, 1 mM Dithiothreitol (DTT). Fab was separated from the 
cleaved Fc fragments and undigested IgG by eluting with a linear 
gradient of 0 to 1 M NaCl in 10 mM Tris-HCl pH 7.5 buffer from a 
Resource Q column (GE Healthcare).  Fab fragments of both 
antibodies were collected in the flow-through and the purity of the Fab 
preparation was determined by running SDS-PAGE gels. Fab of HMAb 
10.15 (Fab 10.15) used in PRNT assay were generated by our 
collaborators directly as a recombinant protein with a His-tag at the 
C-terminus of the heavy chain.  




Barrett, 2007), anti-prM MAb 2H2, 1A1D-2 (Roehrig et al., 1998) and 
anti-fusion loop MAb 4G2 (Henchal et al., 1985) were used in the 
studies. Hybridoma cells were grown in BD Cell MAb Medium in the 
CELLine device (BD Bioscience) and the culture supernatant containing 
secreted antibodies were harvested weekly. The supernatants was 
centrifuged at 2000g for 10 min to remove cell debris and then dialyzed 
to 20 mM sodium phosphate buffer at pH 7.0 at 4°C before filtered 
through a 0.22 μm membrane. The filtered sample was passed through 
HiTrap Protein G HP column (GE Healthcare) and eluted using 100 mM 
glycine-HCl at pH 2.7. The purified Ab was immediately neutralized by 
adding 1 M Tris-HCl at pH 9.0 and then dialyzed against 20 mM sodium 
phosphate buffer at pH 7.0 with 150 mM NaCl. 
2.3 Enzyme-linked immunosorbent assay (ELISA) 
Microtiter plates (Nunc MaxiSorp, Thermo Scientific) were coated 
with purified antigens (E and E-DIII, 0.25 μg/well) overnight at 4oC. The 
plate was then blocked at room temperature for 1 hr with 5% BSA in 
PBST buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4, 0.05% (v/v) Tween 20). Purified IgG 10.15 and 3F9 




temperature for 1 hr. Same amounts of murine monoclonal antibodies 
1A1D-2, 3H5, 4G2 and 2H2 were included as controls for domain 
binding specificity. The plates were washed 4 times with PBST buffer 
prior to incubation with goat anti-human IgG (H+L) HRP-conjugated 
secondary antibodies (Thermo Scientific) for HMAb and goat 
anti-mouse IgG Fc HRP-conjugated secondary antibodies (Thermo 
Scientific) for murine MAb at room temperature for 1hr. The plates were 
washed 4 times with PBST before the reaction was developed by 
adding 3,3’,5,5’-tetramethylbenzidine (TMB) substrates (Bio-Rad) and 
quenched with 1M hydroxide chloride. The absorbance at 450 nm was 
read in Infinity200 microplate reader (Tecan). All ELISA experiments 
were repeated at least twice in duplicates.  
2.4 Western blot  
Purified antigens (E and E-DIII) were either mixed with sample 
loading buffer (10% (w/v) SDS, 0.2 M Tris-HCl pH 6.8, 20% (v/v) 
glycerol, 0.05% (w/v) Bromophenolblue) or mixed with reducing sample 
loading buffer (sample loading buffer with 10 mM DTT) and boiled. The 
samples were separated on SDS-PAGE at 200 V for 30 min. The 




(PVDF) membrane at 15 V for 30min using Trans-Blot Semi-Dry 
Transfer Cell (Bio-Rad). The membrane was blocked in PBST with 5% 
BSA at room temperature for 1 hr and then probed with IgG 10.15 at 
4oC overnight. After four 10-min wash steps with PBST, the membrane 
was incubated with HRP-conjugated goat anti-human IgG H+L 
secondary antibody (Thermo Scientific) at room temperature for 1 hr. 
The membrane was developed with ECL Plus western blotting detection 
reagent (GE Healthcare) and imaged by ImageQuant ET-RCL 
(Bio-rad). 
2.5 Plaque reduction neutralization test  
Plaque reduction neutralization assay (PRNT) was performed for 
HMAb 10.15 and 3F9 with the two DENV2 strains (NGC and PVP94/07) 
on baby hamster kidney 21 cells (BHK-21) as described (Morens et al., 
1985). Full-length IgG and Fab fragment of both antibodies were tested 
in PRNT. BHK-21 (ATCC CCL-100) cells were maintained in RPMI 
1640 (HyClone) supplemented with 10% FCS at 37°C with 5% CO2. 
Eleven 4-fold serial dilutions of each antibody starting from a maximum 
concentration of 100μg/ml were mixed with 30 plaque-forming units of 




The mixtures were incubated at 37°C for 1 hr and 100 μl of these 
mixtures were added to a monolayer of BHK-21 cells in each well of a 
24-well plate in duplicate and incubated at 37°C for another 1 hr. The 
inoculum was removed after incubation and the cells were further 
incubated at 37°C for 3-4 days before they were fixed and stained with 
0.5% (w/v) crystal violet dissolved in 25% (v/v) formaldehyde for 
visualization of the plaques. Percentage of neutralization was 
determined by comparing the numbers of plaques in various antibody 
concentrations to that in the control without presence of antibodies. 
PRNT50 values were defined as the concentration of antibodies causing 
50% reduction of the plaque numbers and determined by non-linear 
regression in GraphPad Prism version 6.01.  
2.6 Surface plasmon resonance (SPR) 
Kinetic parameters of the interaction between HMAb 10.15 and 
recombinant E protein/E-DIII at pH 7.4 were determined by using 
ProteOnTM XPR 36 Surface Plasmon Resonance system (Bio-Rad). 
Approximately 200 response units (RU) of IgG or Fab were immobilized 
to ProteOnTM GLC sensor chip (Bio-Rad) using amine coupling. 




Once stabilized, two-fold serial dilutions of antigens in PBST (0.05% 
(v/v) Tween 20) were injected over the chip at a flow rate of 100 μl/min 
for 180 sec and allowed to dissociate for 600 sec. For interactions with 
E-DIII, the dissociation was not complete at the end of the dissociation 
period. Therefore the chips were regenerated by a wash step with 
glycine-HCl at pH 2.5 at a flow rate of 120μl/min for 15 sec. The 
sensorgrams were double-referenced to correct the response from both 
reference flow cell and blank buffer.  The binding kinetic parameters 
were then determined by fitting to a nonlinear 1:1 Langmuir binding 
model in the ProteOnTM manager software (Bio-rad). Each interaction 
was repeated at least three times.  
2.7 Amide hydrogen/deuterium exchange coupled with mass 
spectrometry (HDX-MS) 
HDX-MS measures the kinetics of deuterium exchange of amides at 
protein backbone because the side chain deuterons will be 
back-exchanged to hydrogen during the washing step in mass 
spectrometry. After deuterium exchange, the reaction is quenched and 
the protein is rapidly digested by proteases such as pepsin. The mass 
of the peptides generated is analyzed by liquid chromatography–mass 




throughout a protein. Amides that are heavily solvent occluded or stably 
engaged in hydrogen bonds through the secondary structure are 
protected from exchange, which results in slow deuterium uptake 
(Englander and Kallenbach, 1983, Guttman et al., 2015). 
Ligand-binding which involves large changes in solvent protection can 
be monitored by HDX-MS with three to five short time points (less than 
30 min) (Baerga‐Ortiz et al., 2002, Pandit et al., 2012, Kim et al., 2011, 
Yamada et al., 2002, Paterson et al., 1990).  
To probe the epitope of HMAb 10.15 on DENV2 E protein, HDX-MS 
was performed with antigens (recombinant E ectodomain and E-DIII) in 
both absence and presence of Fab 10.15. All antigens were purified by 
size-exclusion chromatography and concentrated to approximately 100 
μM before the experiment. The antigen was mixed with Fab 10.15 at a 
molar ratio of 1:1.5 followed by 1-hr incubation on ice. Samples (antigen 
alone or antigen-antibody mixture) were diluted 10 times with D2O 
buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 99.9% D2O) and 
incubated for various time points (0.5, 1, 2, 5 and 10 min) at room 
temperature. Undeuterated sample of just the antigen alone was 
included as negative control. The reactions were slowed down by 




solution with 2.5 M guanidine hydrochloride) to reach a final pH of 2.5. 
The protein was then reduced by a 3-min incubation at near 0oC with 
immobilized TCEP disulfide reducing gel (Pierce) before mass analysis, 
which was conducted by Electrospray ionization quadrupole 
time-of-flight mass spectrometry (ESI-Q-TOF MS) as described 
elsewhere (Wang et al., 2012).  
Briefly, the quenched sample was injected into a pre-cooled 
nano-ACQUITY UPLCs system (Waters Corporation) and digested in 
an immobilized pepsin column (Applied Biosystems) in the system. 
Digested peptides were eluted using an 8–40% (v/v) gradient of 
acetonitrile in 0.1% (v/v) formic acid and resolved with ACQUITY UPLC 
BEH C18 column (Waters Corporation). The masses of the peptides 
were measured using a SYNAPTs High Definition Mass Spectrometer 
(Waters Corporation) acquiring in MSE mode (Shen et al., 2009). 
Deuterium-exchange pattern of each peptide from the antigen in the 
presence and absence of antibody was compared. 
2.8 Structure determination of Fab 10.15 – E-DIII complex by X-ray 
crystallography  
X-ray crystallography is currently the most powerful technique to 




Generally the major bottleneck in crystallography is to obtain a crystal 
that will diffract to high resolution.  
2.8.1 Basic theory 
A protein crystal is composed of an ordered array of protein 
molecules. A unit cell is a smallest volume, which when repeated in 
three dimensional space forms the whole crystal. The general shape of 
the unit cell can be described by using six parameters: the lengths of 
the unit cell edges (a, b, c) and the angles between them (α, β, γ) (Fig. 
2-2).  
 
Figure 2-2 The dimensions of a unit cell. Axes a, b and c and 
inter-axial angles α, β and γ are labeled. 
 
Since the unit cell is repeated to produce a crystal, the electron 
density of the protein molecules in a crystal can be described 
mathematically by a 3D periodic function, each period covering one unit 
cell. The aim of X-ray crystallography experiment is to find this 




crystal is related to the Fourier transform of the electron density within 
the crystal unit cell, known as structure factor, which can be sampled by 
collecting the diffraction pattern in reciprocal space and represented as 
a Fourier series. To this end, a crystal can be viewed as series of 
parallel planes separated by a constant distance. Each set of parallel 
planes can be specified with Miller indices (hkl) where each number 
refers to how many times each plane will cut the respective unit-cell 
edges. W. L. Bragg showed that X-ray beam reflected from each series 
of these planes will interfere constructively only at some specific angles. 
These angle θ can be described with an equation 
                              (2.1) 
In which, dhkl is the interplanar spacing for a particular set of parallel 
planes (hkl) and λ is the wavelength of the incident X-ray beam.  
In a diffraction experiment, locations and intensities of the diffracted 
beams on the detector are recorded. The location of the diffraction spot 
depends on the dimension of the unit cell, whereas the intensity of 
diffraction beam depends on the electron density ρ on planes (hkl) and 
the internal symmetry within the unit cell. The structure factor (the 




Miller indices, which represents the waves that result from the 
diffraction which can be expressed as  
                                      ( )  ∫  ( )    (      )                               (   )
 
      
 
In this equation, each reflected wave is represented by a complex 
number. Since the crystal is just multiple repeats of the unit cell, the 
formula can be limited to the unit cell only. r is the position vector in real 
space and defined as fractions of the unit cell axes, expressed as  
                                                             (   ) 
While s is the reciprocal vector and equal to 
                                                        (   ) 
Where a*, b* and c* are three axes of the reciprocal lattices, which are 
perpendicular to the plane bc (meaning plane formed by axis b and c in 
real space), ac and ab, respectively. Therefore 
     (            )  (        ) 
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From equation (2.2-2.5), one can deduce that: 
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Note that the structure factor is expressed in terms of Miller indices (hkl) 
which can be related to the individual spots in the diffraction pattern. As 
the structure factor is a Fourier transform of the electron distribution in 
real space, the electron density can be regenerated from the structure 
factors with an inverse Fourier transform. This equation called electron 
density equation is expressed as:  
                                           ( )   
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All information of the diffracted waves, including their Miller indices, 
amplitudes and phases, is required in order to produce the electron 
density function and solve the crystal structure. The Miller indices are 
determined from the observed diffraction spots positions, and the 
amplitude is measured in the experiment. However, the phase is not 
directly recorded in a diffraction experiment. The estimation of the 
phase can be obtained in various ways: the direct methods, 
Multiple-wavelength Anomalous Diffraction (MAD), Multiple 
Isomorphous Replacement (MIR), Molecular Replacement (MR). If 
there are available crystal structures homologous to the protein being 
studied, MR is the most straightforward approach for solving the phase 




using the existing homologous structures, calculating the diffraction 
pattern and comparing them with the experimental data. 
Since both DENV envelope protein and human Fab structures are 
available, molecular replacement has been used for the determination 
of DENV E-DIII- antibodies complex crystal structure in this thesis. An 
initial model is built and used to refine the estimates of the phases for 
the data, which should lead to an improved model. The positions of the 
atoms and their respective Debye-Waller factors (B-factor, accounting 
for the thermal motion of the atom) can be refined to fit the observed 
diffraction data to obtain more accurate phases. The refinement is done 
iteratively and the correlation between the diffraction data and the 
model is measured by an R-factor defined as 
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Where Fo is the structure factor observed with the data and Fc is the 
structure factor calculated from the fitted model. A similar quality 
criterion Rfree, developed to prevent over-fitting of the data, is usually 
calculated from a subset (~5-10%) of reflections that are not used in the 
structure refinement. Chemical bonding features are also used to 




and distribution of bond lengths and angles. Omit maps (Fo-Fc) is also 
used to check for phase bias. 
2.8.2 Crystallization of Fab 10.15 – E-DIII complex  
DENV2 E-DIII was mixed with Fab 10.15 in a molar ratio of 1.5:1 
and incubated on ice for 1 hr. Complex was separated from excessive 
E-DIII with a Superdex 75 10/60 size exclusion column (GE Healthcare) 
pre-equilibrated with 20 mM Tris-HCl pH 7.5 and150 mM NaCl. The 
purified complex was concentrated to 12 mg/ml for crystallization 
screen.  
Initial screen was set up in Intelli 96-well sitting drop plates with 
Phoenix crystallization robot (Hampton Research) and incubated at 
20oC. Drops were composed of 0.3 μl protein solution and 0.3 μl 
crystallization solution. Crystals were found in two conditions of the 
PACT premierTM HT-96 screen (Molecular Dimensions) (Fig. 2-3): 
condition B12 (0.1M MES, pH=6.0, 20% PEG6000 and 0.2mM Zinc 
Chloride) and condition D12 (0.1M Tris-HCl pH 8.0, 20% PEG6000 and 







Figure 2-3 Morphology of the crystals obtained in initial screen. (a) 
Crystal grown as needle clusters at condition B12 in PACT premierTM 
HT-96 screen. (b) Crystal grown at all three dimensions at condition 
D12 in PACT premierTM HT-96 screen. Scale bar represents 100 μm. 
 
The optimization was done manually by hanging-drop vapor 
diffusion technique with a bigger drop size comprising of 1 μl protein 
solution plus 1 μl crystallization solution. Parameters that were 
optimized include PEG6000 concentration (5% to 25% in steps of 2.5%), 
buffering pH (7.5 to 8.5 in steps of 0.25), zinc chloride concentration 
(0-2.5 mM in steps of 0.5 mM), protein concentration (3, 6, 9 and 12 
mg/ml) and temperature (4oC and 20oC). Larger, diffracting crystals 
were obtained in presence of 0.1 M Tris-HCl pH 8.0, 9% PEG6000 and 
2 mM zinc chloride. However, very few spots were observed in the 
diffraction pattern, indicating that the crystals were not well packed. 
Therefore, additive screen HT (Hampton Research) was used to further 




adding cadmium chloride hydrate to the crystallization solution at a final 
concentration of 10 mM. Crystals appeared on the second day and 
grew to a maximum size within one week. For data collection, the 
crystals were flash-frozen with mother liquor supplemented with 30% 
glycerol as cryo-protectant. 
2.8.3 X-ray diffraction of Fab 10.15 – E-DIII crystal  
Diffraction data were collected with an in-house X-ray source of a 
wavelength of 1.54178 Å and a Saturn 944 CCD detector (Rigaku) set 
at a distance of 70 cm. One hundred and eighty degrees rotation data 
were collected at 1o oscillation range. The detector to crystal distance 
was set up by considering the balance between maintaining reasonable 
spot separation and preserving higher resolution signals. The exposure 
time was set up to 30 sec per frame to achieve a good intensity for 
higher resolution data while also avoiding pixel overload at the low 
resolution range. The oscillation angle was determined by considering 
factors such as the overlaps of lunes at high resolution and the 
mosaicity of the crystal.  
2.8.4 Crystal structure determination  
The diffraction data were indexed, integrated and scaled using 




determining the unit cell dimension, assigning a Miller index to each 
diffraction spot and finding the unit cell symmetry (the space group). 
Integration over multiple images further refines the crystal, beam and 
detector parameters. Moreover, as symmetry-equivalent data are 
collected multiple times in the data collection process due to the 
symmetry of the crystals, merging and scaling these images put the 
data to a consistent intensity scale. Symmetry-related R-factor (Rsym) is 
used to evaluate how similar the measured intensities of symmetry 
equivalent reflections are and also act as an indicator for data quality. 
The crystal of Fab 10.15 – E-DIII complex diffracted to 2.65-Å and 
belonged to monoclinic C-centered space group C2. Matthews 
coefficient was calculated and number of molecules within one 
asymmetric unit was estimated to be two with an estimated solvent 
content of 50.63%. Using the program Phaser (McCoy et al., 2007), 
initial phase was obtained by MR method using the coordinates of 
DENV-2 E-DIII (extracted from PDB code 2R69) and the Fab fragment 
of an anti-influenza virus IgG 1F1 (PDB code 4GXU) as search models. 
Iterative cycles of model building and refinement were performed by 
using the program Coot (Emsley et al., 2010) and Phenix.refine 




analyzed using Molprobity (Chen et al., 2009). The details of the 
parameters for the final structure are listed in Table 3-2.  
2.9 Cryo-EM study of virus – antibody complex  
2.9.1 Introduction of cryo-EM single particle analysis 
Cryo-electron microscopy (cryo-EM) is a powerful technique in 
structural biology. In cryo-EM experiment, the sample suspended in 
buffers is frozen into vitreous ice on cryo-EM grids and thus imaged in a 
near native state. Biological macromolecules (proteins, RNA, etc.) are 
composed of mostly light atoms: carbon, oxygen, nitrogen, sulfur, and 
phosphorus, which do not interact strongly with electron beam. Because 
of that, vitrified biological specimens produce very low contrast images 
in the electron microscope. Hence, in order to improve contrast, vitrified 
sample is imaged at a range of underfocus value. This imaging 
technique takes advantage of the wave properties of the electron beam 
where the phase contrast generated by the interaction of the beam and 
sample is converted into amplitude contrast, which is recorded by the 
detector. Several factors are important for optimization of data collection, 
such as electron dose, defocus range, energy of electrons used etc. 




away from focus will result in the loss of high resolution signal but 
increased in contrast. Defocus range used therefore depends on 
whether contrast or obtaining high resolution signal is preferable. 
Electron dose for data collection is also another important factor as 
increased dose also increases contrast but the radiation can damage 
the structure of the particle leading to a loss in resolution. Typically, a 
dose of about 20e-/Å2 is considered acceptable (Cheng, 2015).  
There are three common cryo-EM techniques to obtain 3D 
reconstruction of macromolecule, namely 2D crystallography, 
tomography and single particle analysis. The 2D crystallography 
determines the structure of macromolecules arranged in the form of 2D 
crystals. In tomography, a series of images of the same object tilted at 
different angles around a fixed axis is taken and then computationally 
processed to obtain a 3D reconstruction of the macromolecule. This 
thesis employs the use of the third technique: single particle analysis. It 
involves a collection of 2D projections of many different views of the 
same macromolecule. The orientations of these 2D projections are 
determined and then computationally aligned to each other to obtain a 




camera and reconstruction algorithms, single particle analysis can now 
achieve atomic resolution (Bartesaghi et al., 2015, Campbell et al., 
2015, Grant and Grigorieff, 2015, Jiang et al., 2015, Fischer et al., 
2015).  
Basic steps of single particle analysis are: particle selection, 
contrast transfer function (CTF) correction, 2D classification, initial 
model generation, model-based 3D classification and refinement, 
resolution assessment, and interpretation of the 3D density maps. More 
detailed introduction of these procedures can be found in some recent 
reviews (Cheng, 2015, Bai et al., 2014, Henderson et al., 2012).  
2.9.1.1 Correction of contrast transfer function (CTF) 
The CTF must be first corrected in order to properly recover the 
high resolution information recorded in a cryo-EM image. An electron 
beam is considered as a wave whose phase and amplitude are subject 
to change upon passing through materials with altering properties. The 
CTF describes the influence of imperfections of the microscope and 
choice of imaging conditions on the final image. These include angular 




the lenses, specimen drift, specimen vibration, underfocus, noise from 
the microscope, and the detector's nonlinearity of response and its own 
noise. To obtain a faithful 3D reconstruction of the structure to a 
resolution better than 10 – 15 Å, the images should be corrected for the 
influence of the CTF. As stated in (Ludtke et al., 1999), the data 
measured in a transmission electron microscope can be described as: 
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In which s is the spatial frequency, M(s) is the measured data, F(s) is 
the structure factor of the molecule, CTF(s) is the contrast transfer 
function, E(s) is the envelope function and N(s) is the mean noise 
intensity. The CTF can be estimated by using the averaged power 
spectrum of the image and summarized as  
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In which k is the scaling factor, A is the percentage of amplitude contrast, 
Cs is the spherical aberration coefficient, λ is the electron wavelength, 
Z0 is the object lens defocus and Z is the focal difference due to axial 




and +1 (positive contrast transfer) as it goes from low to high spatial 
frequencies with some locations having zero crossings and resulting in 
information loss (Fig. 2-4)  
The major contributors to the envelope functions are the spherical 
aberration Cs and the current/voltage instabilities, which limits the 
spatial and temporal coherency of the beam, respectively. The envelope 
function can usually approximate Gaussian envelope function: 
                                                         ( )       
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The combined effects of CTF and envelope function become more 
noticeable at higher spatial frequencies, ultimately limiting the 
achievable resolution (Fig. 2-4). 
 
Figure 2-4 The contrast transfer function and envelope function. 




The amplitude of the CTF is attenuated towards higher resolution by a 
near Gaussian envelope function. Figure extracted from (Mindell and 
Grigorieff, 2003). 
 
In addition, noise should be properly estimated to retrieve the signal 
in the micrographs. There are many ways to estimate the noise. For 
example, in the EMAN software package (Ludtke et al., 1999), the noise 
profile is approximated by an empirical four parameters function: 
N2(s) = n1 exp (n2 s +n3 s2 + n4s1/2)        (2.13)  
In summary, defocus is the only arbitrary parameter for the same 
sample during cryo-EM imaging. Features of the object at different 
resolutions appear distorted in the image depending on the defocus 
setting. Images are usually collected at several different defocus values 
to allow for proper recovery of information at all spatial frequencies 
(Penczek et al., 1997). 
2.9.1.2 Particle alignment  
Besides CTF correction, another fundamental step to obtain the 3D 
structure of the molecule is particle alignment. Particle images need to 
be aligned relative to each other and averaged to obtain an image with 




five alignment parameters: three orientation Euler angles (θ, ϕ and ω) 
defining the direction of view of the object (Fig. 2-5) and two translation 
parameters (x, y) defining the center position of the object in the image. 
One of the methods used for particle alignment is the common lines 
method (Crowther et al., 1970). A common line is the intersection line 
where the Fourier transforms of any two projections coincide. The 
central section theorem states that Fourier transform of a 2D projection 
of a 3D object forms a central section in the 3D Fourier transform of the 
same object. Therefore it is possible to estimate a relative orientation of 
a projection when compared to a projection that has a defined 
orientation. The method to derive orientation by comparing projections 
of different particles is called cross-common line method. For highly 
symmetric objects, such as icosahedral viruses, there are many 
self-common lines, allowing determining the approximate alignment 
parameters from a single image (Baker et al., 1999). This method is 






Figure 2-5 Definition of particle orientation of an icosahedron 
object. θ, φ, and ω angles together define the orientation in which an 
icosahedral particle is viewed. Any view vector can be transformed to a 
view of the single asymmetric unit (shaded region) due to the 
icosahedral symmetry. Figure from (Baker et al., 1999). 
 
Search for the orientation is usually conducted using either the 
self-common line or the cross-common line method. This initial search 
for the center and orientation can be done either sequentially (first to 
find the center and then search for orientation with the pre-fixed center) 
or simultaneously (procedures implemented in Multi-Path 
Simultaneously Annealing (MPSA), the algorithm used in 3D 
reconstruction of the DENV2 - Fab 10.15 samples) (Liu et al., 2007). 
Refinement of the center and orientation is generally conducted locally 
using cross-common lines between particle images and reference 




Considering that signal from the sample is low in the cryo-EM image, 
particle alignment based on cross-correlation can sometimes produce 
unreliable result. To tackle this, different strategies are implemented in 
various algorithms. One of the algorithms, MPSA, validates the 
correctness of the determined orientation of a particle image by 
checking for consistency in the result when the orientation search is 
repeated several times. Particles with inconsistent orientations are 
discarded from further processing. In another method based on 
maximum likelihood approach, all possible orientations are tested, by 
comparing systematically with all projections of a 3D model. Each 
orientation is assigned a weight and with the weights taken into 
consideration, all possibilities are used to make a 3D map. This 
approach is implemented in Relion (Scheres, 2010b, Scheres, 2010a).  
Once the center and orientation of each particle image is determined, 
they are combined together to generate a 3D structure using the 
projection-slice theorem. An iterative routine using the generated 3D 
map as a model for next cycle of particle alignment is proven to be 
useful to obtain a more precise alignment, leading to the convergence 




Some samples can be heterogeneous in structure. To sort particles 
into different structural groups, maximum-likelihood approach can be 
applied at both 2D (Scheres et al., 2005) and 3D levels (Scheres et al., 
2007). The 2D classification is also used to remove broken and 
abnormal particles from the image reconstruction process.  
2.9.1.3 Resolution assessment 
For resolution estimation of cryo-EM density map, Fourier shell 
correlation (FSC) is currently the most accepted method. It is defined as 
the spatial frequency at which two reconstructions each generated from 
a different half of a dataset are comparable with each other at a chosen 
correlation threshold. Different correlation threshold cutoff have been 
proposed. The accepted value is 0.5 for low to intermediate resolution 
(worse than 10 Å), and 0.143 for higher resolution structures (Rosenthal 
and Henderson, 2003). Recently, the method termed “gold standard 
FSC” has been proposed (Henderson et al., 2012), where comparison 
are done with the half datasets that are reconstructed independently 
from the beginning of the iterative cycles of orientation search and 3D 
reconstruction procedure. In this thesis, resolution assessment was 




2.9.2 Preparation of DENV2 – Fab complex and cryo-EM data 
collection 
Both DENV2 strains NGC and PVP94/07 were mixed with Fab 
10.15 at a molar ratio of three Fab molecules for every two E proteins 
on the surface of the virus. Both these complexes were incubated at 4, 
or 28, or 37°C, followed by 2 hrs at 4°C. The control samples without 
Fab were incubated at the same temperatures. For HMAb 3F9, only 
DENV2 PVP94/07 strain was used and the virus was mixed with Fab 
3F9 at a similar molar ratio as when preparing the Fab 10.15 sample. 
The complexes were incubated at either 4 or 37°C for 2 hrs prior to 
freezing on cryo-EM grids. 
 Approximately 2.5 μl drop of each sample was pipetted onto 
ultra-thin carbon-coated lacey carbon grids (Ted Pella). The grids were 
then blotted with filter papers for 2 sec and flash-frozen in liquid ethane 
using the Vitrobot Mark IV plunger (FEI). The frozen grids were kept at 
liquid nitrogen prior to imaging. The sample was imaged using a 300-kV 
Titan Krios electron microscope (FEI) at 47,000X magnification with an 
electron dose of 18 e-/Å2. At a range of underfocus value to provide 
phase contrast. The images were collected on a direct electron detector 




Since Fab 10.15 was found to bind more efficiently to both DENV2 
strains NGC and PVP94/07 at 37oC as compared to other temperatures 
(Fig. 3-11), images of Fab 10.15 complexed with both NGC and 
PVP94/07 incubated at 37°C were used for manual data collection. Fab 
3F9 bound equally well to DENV2 PVP94/07 at both 4oC and 37oC. The 
sample at 4oC was used for data collection due to additional 
consideration that at low temperature the complex might be less mobile, 
which may lead to the attainment of a higher resolution map. Similar 
microscopic parameters were used to collect images of DENV2 - Fab 
3F9 sample as the DENV2 – Fab 10.15 sample, except automated data 
collection software, Leginon, was employed (Carragher et al., 2000).  
2.9.3 Single particle analysis of DENV2 – Fab complexes  
Firstly, cryo-EM micrographs were analyzed and those showing 
obvious drift and astigmatism were discarded. Micrographs with 
defocus values between 0.5 to 3.5 μm were used for image 
reconstruction process (Table 2-1). Images of individual particles were 
manually selected in the micrograph and extracted using e2boxer from 
EMAN2 software package (Tang et al., 2007). Pixels containing extreme 
intensities were removed from the extracted images and the particles 




astigmatic defocus implemented in program CTFFIND3 was used for 
determination of the CTF parameters (Mindell and Grigorieff, 2003). For 
all datasets, before icosahedral reconstruction, particles were always 
sorted through reference free 2D classification to remove broken and 
abnormal particles using maximum likelihood method implemented in 
Relion (Scheres, 2012).  
For HMAb 10.15, the sample of DENV2 NGC – Fab 10.15 complex 
was more heterogeneous than PVP94/07 – Fab 10.15 complex (Fig. 
3-12, Fig. 3-14). This could be due to the structural flexibility of the 
DENV2 NGC strain. Orientation assignment was performed using 
MPSA (Liu, 2007) followed by 3D reconstruction using the Make3D 
program from EMAN (Ludtke et al., 1999). Resolutions of the maps 
were determined by plotting the FSC coefficient between 
reconstructions from two half datasets refined independently from the 
start with a cutoff value of 0.5. Initial models and statistics of final 
reconstructions are listed Table 2-1.  
Unlike the approach in analyzing the DENV2 - Fab 10.15 datasets, 
a maximum likelihood method implemented in Relion was used 
throughout the processing of DENV2 – Fab 3F9 dataset (Scheres, 




to this program, particles were first sorted by reference free 2D 
classification, followed by 3D classification. After the 3D classification 
runs (with parameter K=5, i.e. request the algorithm to generate 5 
classes) with different initial models, majority of the particles were 
always sorted into a single class. Since the 3D maps which were 
reconstructed from these particles were always similar to each other, 
one of these maps was used as the initial model for 3D refinement. To 
avoid the problem of over-fitting in iterative reconstruction, the 3D 
refinement was conducted whereby the dataset was divided into 
random halves and reconstructed separately. An FSC curve between 
the two independent reconstructions is calculated at the end of every 
cycle to estimate the resolution-dependent SNR, which is then used to 
filter the maps. The convergence of the final structure is monitored by 
the accuracy of rotation and translation assigned to the particle images. 
Only upon convergence, the two halves of the data were then combined 
to calculate a single map accounting for all particles. The resolution is 
reported as the spatial frequency at a cut-off of 0.143 correlation of the 






Table 2-1 Information of cryo-EM 3D reconstruction of Fab in 





NGC- Fab 10.15 




Relion + MPSA + 
Make3D in 
EMAN   
Refine2D in 















285 361 791 
No. of particle 
selected 
2351 8292 8652 




2186 (93.0%)a 3831 (46.2%) 4891 (56.5%) 
No. of particle in 
final 
reconstruction 
1463 (62.2%) 2762 (33%) 4891 (56.5%) 
Resolution (Å) 24 22 22 
a 
Numbers in the parentheses indicate the percentage of the particles in all 
selected particles. 
 
2.9.4 Fitting of the DENV2 - Fab 10.15 cryo-EM density map  
The pixel size of the map was confirmed by comparing the radius of 
its lipid bilayer with a low-pass filtered high-resolution DENV2 mature 
virus cryo-EM map. Due to its low resolution, interpretation of the Fab 




DENV2 mature virus structure (PDB code 3J27) and the crystal 
structure of E-DIII and Fab 10.15 into their corresponding cryo-EM 
densities in the program “O” (Jones et al., 1991).  
For the DENV2 – Fab 3F9 complex, the interpretation of the 
cryo-EM density map was carried out by manually fitting with the Cα 
chain of the E protein and a Fab (using the structure of Fab 10.15 as a 
substitute) by using the program “O” (Jones et al., 1991). All structural 
figures were made using the program “Chimera” (Pettersen et al., 
2004). 
2.10 Dynamic light scattering to determine size of immune 
complex  
The size of the immune complex was determined by using 
dynamics light scattering (DLS) (Stieh et al., 2014). This technique 
utilizes a time-correlation function to determine the sizes of particles 
which diffuse in a solution due to Brownian motion. Sample that 
self-correlates for a longer period is larger in size than those of which 
time-correlation functions decrease more rapidly. The slope of the 
time-correlation function reflects the polydispersity of the sample and a 
steeper slope of the time-correlation function indicates more 




diameter obtained from this method is the diameter of a sphere with the 
same diffusion coefficient as the sample. 
In our experiment, purified virus particles in NTE buffer were used 
at a concentration of 50 μg/ml of E proteins. Serial dilutions of IgG were 
mixed with the purified virus in a 1:1 volume ratio and the mixtures were 
incubated at 37oC for 30 min before the measurement. A volume of 15 
μl for each reaction was loaded into a Quartz cuvette for measurement 
at 37oC by Zetasizer Nano S machine (Malvern instrument). Data were 
analyzed using Zetasizer Nano software version 6.01. Ten readings 
were collected for each measurement of one duplicate and the reported 
diameters are averages of duplicate measurements. 
2.11 Structural analysis 
Buried surface areas of the antibody-antigen interface were 
calculated with the PISA server (Krissinel and Henrick, 2007). LSQ 
superpose in COOT was used for superimposition of protein structures. 
Electrostatic properties of the protein were presented based on 
Coulomb potential surface coloring using Chimera (Pettersen et al., 
2004).  Epitope accessibility was represented as the percentage of 




neighboring E proteins. This was calculated by dividing the sum of the 
SSA of all residues of the epitope in presence of neighboring E proteins 
by the corresponding sum in absence of neighboring E proteins. The 
SSA was calculated using CCP4 program AREAIMOL with a 1.4-Å 
radius sphere as a probe. 
2.12 Sequence variation analysis 
In total, 1,097 DENV2 E protein sequences were downloaded from 
NCBI database and submitted to ViPR web server for protein sequence 
variation analysis (Pickett et al., 2012).  
2.13 Statistical analysis 
Unpaired t-test was used to check whether any difference in means 
observed in the experiment was statistically significant (P<0.05). All 









Chapter III. DENV2-specific Neutralizing HMAb 10.15  
3.1 HMAb 10.15 binds to recombinant E protein and E-DIII  
HMAb 10.15 was previously found to be DENV2-specific and its 
neutralization potency was evaluated in a standard PRNT assay with 
various DENV2 strains. Some DENV2 strains, both laboratory-adapted 
and clinical isolates, were neutralized by this antibody at picomolar 
concentrations (Teo, 2014). In addition, this antibody can significantly 
increase the survival rate of AG129 mice infected by DENV2 strain 
D2Y98P-PP1 at concentration of 250 μg per mouse (Teo, 2014) 
As shown in Fig. 3-1, anti-prM antibody 2H2 did not bind to either 
recombinant E protein or E-DIII. In comparison, anti-DIII antibody 3H5, 
could bind to both E protein and E-DIII whereas an anti-DII fusion loop 
antibody 4G2 only recognized E protein but not E-DIII. HMAb 10.15 
behaved similarly to 3H5 with binding specificity to both E protein and 






Figure 3-1 HMAb 10.15 binds to both recombinant E and E-DIII. 
Binding of murine MAbs 3H5, 4G2 and 2H2 and, HMAb 10.15 to 
recombinant DENV2 E protein and E-DIII. BSA was employed as a 
control antigen in this indirect ELISA. 
 
In western blot analysis, HMAb 10.15 bound strongly to the 
non-reduced form of recombinant E and E-DIII in semi-denaturing 
condition. The binding to the reduced form of both proteins, on the other 
hand, was much weaker (Fig. 3-2). This suggested that HMAb 10.15 
recognize a conformational dependent epitope within E-DIII. HMAb 
10.15 bound to the E protein with an affinity of 8.85 nM and a half-life of 





Figure 3-2 Binding analysis of HMAb 10.15 by western blot. Binding 
of HMAb 10.15 to recombinant DENV2 E protein and E-DIII at 




Figure 3-3 Kinetics analysis of HMAb 10.15 interaction with DENV2 
recombinant E protein. SPR traces are presented of HMAb 10.15 
interacting with E protein. The experimental curves were fitted using 1:1 
Langmuir analysis to determine the kinetic parameters presented in 
Table 3-1. Binding curves at different antigen concentrations are 
labelled pink (40 nM), cyan (20 nM), blue (10 nM), green (5nM), 








Table 3-1 Kinetics of HMAb 10.15 binding to E protein measured by 















E 2.13±0.18 11.82±1.13 8.85±1.25 32.94±9.19 
akD = kd/ka 
bt1/2 = ln(2)/Kd 
 
3.2 Crystal structure of Fab 10.15 - E-DIII complex 
Fab 10.15 was complexed with E-DIII (amino acid 295-395) from 
DENV2 strain PVP94/07 and the crystal structure of this complex was 
determined to 2.65-Å resolution (model statistics in Table 3-2). The 
observed root mean square deviation (r.m.s.d.) of only 0.75 Å between 
all equivalent Cα atoms in E-DIII and crystallized DENV2 E protein 
(Modis et al., 2003) suggested that binding of Fab 10.15 caused no 
major perturbation to the E-DIII structure. 
The surface areas of the interface were 656.4 Å2 and 679.2 Å2 in 
E-DIII and Fab 10.15, respectively. The paratope of the Fab consisted 
of all six complementary determining regions (CDRs), H1 - H3 and L1 - 
L3, resulting in a total of 13 residues (nine from heavy chain, four from 
light chain) (Fig. 3-4a). Sixteen residues in E-DIII constituted the 
epitope and they were mostly located in A-strand, FG loop and G-strand 




interacted with the heavy chain of the Fab and it was centered on a 
hydrophobic groove formed by residues from A- and G-strands (Fig. 
3-4b). Two residues, Lys305 and Lys307, interacted with both heavy 
and light chains of Fab 10.15, whereas residues Glu327 and Pro384 
interact only with the light chain (Fig. 3-4b). There were twelve 
hydrogen bonds and some hydrophobic interactions in the interface 
(Table 3-3). Six of these hydrogen bonds involved main chain atoms, 
Phe306(O), Val308(O), IIe312(N), Gln386(O), Lys388(N) and 
Ser390(N), of E-DIII (Table 3-3). The CDR-H3 of HMAb 10.15 made 
extensive interactions with both A- and G-strands of DIII. For instance, 
side chains of two bulky hydrophobic residues Tyr105 and Trp109 in 
CDR-H3 could bind to the hydrophobic groove formed by A- and 
G-strands (Fig. 3-4c). This hydrophobic interaction was further 
stabilized by hydrogen bonds formed between residues in CDR-H3 and 
residues in both A- and G- strand of E-DIII (Table 3-3). The epitope and 
paratope were highly complementary in shape (i.e. shape 
complementarity value = 0.656), typical for antibody-antigen 






Table 3-2 Data collection and refinement statistics (molecular 
replacement) for Fab 10.15 - E-DIII complex.  
 Fab 10.15 – E-DIII 
Data collection  
Space group C2 
  
a, b, c (Å) 129.509, 53.208,91.283 
α, β, γ (o  90, 108.911, 90 
Resolution (Å) 23.21 – 2.65 Å (2.74 – 2.65 Å)  
Rsym or Rmerge 0.054 (0.312) 
I / σI 19.668 (4.857) 
Completeness (%) 99.0 (96.8) 
Redundancy 3.4 (3.2) 
  
Refinement  
Resolution (Å) 23.21 – 2.65 Å (2.74 – 2.65 Å) 
No. reflections 17084 
Rwork / Rfree 0.24 / 0.28 








R.m.s. deviations  
Bond lengths (Å) 0.003 
Bond angles (o) 0.79 
Values in parentheses are for highest-resolution shell. 
Rwork = Σhkl||Fobs| - |Fcalc||/Σhkl |Fobs|, which is the crystallographic R-factor 
and calculated with 90% of the data used in the refinement; Rfree is another 
crystallographic R-factor calculated with 10% randomly selected data which is 





Figure 3-4 The crystal structure of Fab 10.15 complexed with 
DENV2 E-DIII.  
(a) A ribbon diagram showing the crystal structure of Fab 10.15 - E-DIII 
complex. The light chain and heavy chain are colored in green and 
yellow, respectively, with residues constituting the paratope as spheres. 
The E-DIII is colored in cyan with the residue forming the epitope as 
magenta spheres. (b) Surface representation of the epitope with surface 
contacted exclusively by light chain, heavy chain and both chains 
colored as green, yellow and blue, respectively. Residue numbers and 
amino acids are labelled. (c) A close-up view of the CDR-H3 binding to 
the hydrophobic groove formed between A- and G-strands of E-DIII, 
with the same color scheme as (a). Side chains of contact residues are 
shown as sticks with hydrogen and oxygen atoms colored as blue and 
red, respectively. Residues W105 and Y109 in CDR-H3 with 
hydrophobic side chains are labelled. Potential hydrogen bonds are 








Table 3-3 List of potential hydrogen bonds based on the 2.65-Å 
resolution crystal structure of Fab 10.15 – E-DIII complex. 
 
E-DIII Fab fragment 
Distance (Å) 
Position Residue CDR Position Residue 
305 Lys (NZ) 
L3 114 Asp (OD1) 2.58 
L1 52 Asn (OD1) 2.37 
306 Phe (O) H3 109 Trp (NE1) 3.01 
307 Lys (NZ) L2 71 Ser (OG) 4.00 
308 Val (O) H3 104 Leu (N) 3.96 
311 Glu (OE2) H1 33 Asn (ND2) 3.36 
312 Ile (N) H3 105 Tyr (OH) 3.06 
327 
Glu (OE1) L1 53 Thr (OG1) 3.86 
Glu (OE2) L2 71 Ser (OG) 3.68 
386 Gln (O) H3 108 Gly (N) 3.55 
388 Lys (N) H3 107 Ser (OG) 3.44 
390 
Ser (N) H2 55 Tyr (OH) 2.96 
Ser (OG) H2 56 Asp (OD1) 3.00 
Red color highlights DIII main chain atoms potentially involved in the hydrogen 
bond interaction with Fab 10.15 
 
This epitope was highly conserved in DENV2 with only residue 390 
showing significant polymorphism. Of 1097 DENV2 sequences 
analyzed, 86% have an asparagine (e.g. NGC) at residue 390 while 10% 
have a serine (e.g. PVP94/07) and 4% aspartic acid. In contrast, 




this epitope region (Fig. 3-5e). These changes might disrupt the shape 
and charge complementarity between HMAb 10.15 and E-DIII, 
explaining the serotype specificity of this antibody (Fig. 3-5a, b, c, d). 
 
Figure 3-5 Comparison of electrostatic charges of the epitope 
across DENV serotypes. Electrostatic potential surfaces of E-DIII are 
colored blue (positive), red (negative) and white (neutral). (a) 
Representation of the electrostatic potential of DENV2 E-DIII (left) and 
Fab 10.15 (right) interface. Borders of the epitope and paratope are 
indicated with dashed line. Residues in the epitope that were mutated in 
other serotypes, which might reduce the charge complementarity, are 
highlighted (left). Residues in the paratope are labeled (right), with 
heavy (H) and light (L) chains indicated after the residue numbers. The 




DENV4 of the same region as epitope in DENV2 are shown. (e) 
Sequence alignment of the epitope region of DENV1-4. Residues 
interacting with heavy, light and both chains are highlighted in yellow, 
green and magenta boxes, respectively. Secondary structure and 
residue numbers are indicated above the sequence. Electrostatic 
potential surface were calculated using PDB code 4FFZ (DENV1), 
3VVT (DENV3) and 3WE1 (DENV4) and their sequences were also 
used for alignment. 
3.3 HDX-MS result is consistent with the crystal structure  
In the HDX-MS experiment using E-DIII, the coverage of 
pepsin-digested peptides was 67.7% of the E-DIII sequence. One 
peptide in A-strand (residues 307-313) and multiple peptides extending 
from F-strand to G-strand (from residues 377 to 391) showed significant 
reductions of deuterium uptakes (with cut-off value = 0.5 Da) in 
presence of Fab 10.15 (Fig. 3-6a). As there were overlapping peptides 
for this region, comparisons of their deuterium-uptake differences could 
be conducted.  Alterations of deuterium uptakes for peptide 378-387 
and peptide 378-389 showed approximately one dalton difference, 
similar to the difference observed between those of peptide 377-387 
and 377-389 (Fig. 3-6b). Similar result was also observed between 
peptide 378-389 and peptide 378-391. These differences indicated that 
residues 388-389 and 390-391, located in G-strand, became much 




was consistent with our crystal structure which showed that the amides 
of residues 388 and 390 directly formed hydrogen bonds with the side 
chains of Ser107 and Tyr55 in heavy chain of Fab 10.15, respectively 
(Table 3-3).  
One peptide (residues 312-322) which extended from AB loop to 
B-strand showed increased deuterium uptake in the presence of Fab 
10.15 (Fig. 3-7a). Comparison of the alterations of deuterium uptakes 
between this peptide and two overlapping peptides (peptides 312-321 
and 313-321) suggested that residue 322 located in the B-strand might 
be the residue that contributed to this increase. When the E-DIII 
structure in the complex was compared with the E-DIII in the DENV2 E 
protein crystal structure (PDB code 1OAN), a positional shift of A-strand 
was noticed. This conformational change was presumably caused by 
the binding of Fab 10.15 (Fig. 3-6c) which resulted in changes of the 
hydrogen bonding network around residue 322.  
There was another area with peptides (peptides 352-366, 352-377 
and 360-377) showing reduction of deuterium exchange larger than 0.5 
Da. A closer examination of shorter peptides (including peptides 
352-359, 360-366, 360-367, 367-377) in the same region did not show 




of deuterium exchange for the first residue in any peptide is lost due to 
peptic cleavage. Considering this, comparison of the overlapping 
peptides suggested that residue 360, located in the DE loop, might be 
the key residue causing the reduction. However, examination of this 
residue in our crystal structure did not show obvious conformational 







Figure 3-6 Comparison of deuterium exchange between E-DIII in 
absence and presence of Fab 10.15.   
(a) The difference plot of the deuterium exchange of E-DIII in presence 
and absence of Fab 10.15. Coloring scheme of the results at different 
time points are indicated by the color key. A positive value of the 




suggesting that the peptides are more buried, whereas the negative 
value means the opposite. Peptides are numbered according to the 
sequence of full-length E protein and the secondary structure of E-DIII 
is attached below with the numbers indicating the start and end 
residues of the β–strands. A difference larger than 0.5 Da is considered 
significant, highlighted as green dashed line in the plot. (b) Comparison 
of deuterium exchange differences for multiple peptic peptides at the 
N-terminus of E-DIII. (c) Superimposing the E-DIII structure (cyan) of 
the Fab 10.15 – E-DIII complex with the unbound E-DIII structure (pink) 
(extracted from PDB code 1OAN). The * highlighted the region where 
conformational changes happen and residue 322 showing increased 
deuterium uptake was shown in sticks. (d) Overlapping peptides in 
region 352-377 with sequence numbers plus deuterium exchange 
difference in parenthesis. (e) Results from HDX-MS mapped onto the 
crystal structure of E-DIII in the Fab 10.15 – E-DIII complex. Color keys 
are indicated in the figure. 
 
Another HDX-MS experiment was conducted by using recombinant 
E protein ectodomain instead of E-DIII. In this experiment, 
pepsin-digested peptides covered 69% of the E protein ectodomain 
(amino acid 1-395) sequence. Region 378-389 consistently showed 
reduction of deuterium uptake in presence of Fab 10.15 (Fig. 3-7a). 
However, there was no obtained peptide covering A-strand in this 
experiment. In addition, peptide 313-322 did not show increase of 
deuterium uptake. Thereby residue 322 might not show increase of 
deuterium uptake similar as in the experiment with E-DIII. Moreover, the 
reduction of deuterium uptake for peptides spanning DE loop (where 




experiment with E-DIII as antigens (Fig. 3-6a, Fig. 3-7a). These results 
could be due to varied protein dynamics of E-DIII in absence or 
presence of E-DI/II. Besides, this experiment also provided information 
about the protein dynamics for DI/II of E protein after it was bound by 
Fab 10.15. There was reduced deuterium uptake in peptide 131-159 in 
presence of Fab 10.15, indicating that this region had become more 
buried. This peptide is close to the DE loop of DIII in the E protein 





Figure 3-7 Comparison of deuterium exchange between E proteins 
in absence and presence of Fab 10.15.   
(a) The difference plot of the deuterium uptake of E protein in presence 
and absence of Fab 10.15. Coloring scheme of the results at different 
time points are indicated by the color key. The meaning of positive and 
negative values are the same as Fig. 3-6. Peptides are numbered 
according to the full-length E protein. The 0.5 Da cut-off is highlighted 
as dashed line. (b) HDX-MS results are mapped onto DENV2 E protein 
structure (PDB code 1OAN) in ribbon view with color key attached 
below.  
 
3.4 The amount of HMAb 10.15 required to neutralize DENV2 
strains NGC and PVP94/07 differs 
There were significant differences (P < 0.001) in the PRNT50 value 
for HMAb 10.15 with DENV2 strain NGC (3.5 ± 0.5 ng/ml) and strain 
PVP94/07 (59.4 ± 12.1 ng/ml) (Fig. 3-8a). Similar trend was observed 
with the Fab of this HMAb except that much more Fab were required 
(PRNT50 NGC; 293.6 ± 67.5 ng/ml, PRNT50 PVP94.07; 3649 ± 1090 
ng/ml) (Fig. 3-8b, Table 3-4).  
 
Figure 3-8 Neutralization of DENV2 strains NGC and PVP94/07 by 
HMAb 10.15 and Fab 10.15 in BHK-21 cell. Neutralizations of 50% 





Table 3-4 Summary of PRNT50 values for HMAb 10.15. 
PRNT50 (μg/ml) 
HMAb 10.15 
NGC PVP94/07 PVP94/07 : NGC 
Fab  293.6 ± 67.5 3649 ± 1090 12 
IgG  3.5 ± 0.5 59.4 ± 12.1 17 
 Fab : IgG 84 61 
 
 
3.5 Neutralization potency difference is not due to variation of the 
binding affinity 
Variation within the epitope site and surrounding regions might 
affect the binding of HMAb 10.15 to the virus, leading to the difference 
between sensitivity of NGC and PVP94/07 to neutralization. Sequence 
alignment of the epitope on E-DIII between DENV2 strains PVP94/07 
and NGC showed that only one residue, 390, was different. While strain 
NGC has an asparagine, PVP94/07 has a serine at this position. 
Although the bulkiness of their side chains is different, both are 
uncharged polar residues. The binding kinetics of HMAb 10.15 to these 
two virus strains were measured using recombinant E-DIII bearing 
sequences of these two strains as mobile analyte through the 
immobilized antibodies, either full-length IgG or Fab, in surface plasmon 
resonance (SPR) experiment.  
The results showed that IgG 10.15 had a higher affinity towards 




Similar result was obtained when Fab fragment was immobilized on the 
chip to capture E-DIII in the flowing phase (Table 3-5). HMAb 10.15 has 
higher neutralization potency towards NGC than PVP94/07. In contrast, 
the opposite is true in terms of the affinity. In conclusion, the different 
neutralization potencies of HMAb 10.15 against NGC and PVP94/07 
are not due to its differences in binding affinities to the different E-DIII 
DENV2 strains. It is thus possible that the mobility of the quaternary E 
protein structures on the virus surface may expose its epitope and lead 
to the observed differences in neutralization. 
 
Table 3-5 Kinetics of HMAb 10.15 binding to recombinant E-DIII 


















3.08 ± 1.64 0.87 ±0.44 0.29±0.09 996 ± 529 
E-DIII 
(NGC) 




1.95±1.10 1.06±0.27 0.60±0.20 677±173 
E-DIII 
(NGC) 
1.09±0.39 1.13±0.29 1.14±0.51 641±160 
akD = kd/ka 





3.6 Analysis of epitope accessibility of HMAb 10.15 on DENV2 
mature virus structure  
Analysis of the epitope accessibility on DENV2 compact 
unexpanded mature virus structure at 28oC (PDB code 3J27) revealed 
that 35%, 26% and 25% of this epitope were buried in molecules A, B 
and C, respectively, due to intra-dimeric, inter-dimeric and inter-raft 
interactions (Fig. 3-9a, b). However, as the E protein shell expanded of 
the NGC strain at human physiological temperatures, this epitope 
became more exposed. The proportions of the buried epitopes in 
molecules A, B and C were reduced to 7%, 0% and 1%, respectively 
(Fig. 3-9b). Although E-DIII of molecule B has been elevated in this 
expanded structure with the binding site of HMAb 10.15 becoming fully 
exposed, epitopes in molecules A and C were still occluded by their 





Figure 3-9 Epitope accessibility of HMAb 10.15 on DENV2 mature 
virus structure.  
Left, the epitope of HMAb 10.15 in one asymmetric unit of (a) 
unexpanded and (b) expanded DENV2 mature virus structures. The E 
protein is shown as surface, and mols A, B and C are colored as orange, 
grey and blue, respectively. The epitope of HMAb 10.15 is colored 
magenta. The triangle indicates one asymmetric unit on virus surface 
with symmetric vertices numbered.  
Right, mols A, B and C are represented as ribbons and colored by 
domains (blue for E-DIII and red for E-DI). The epitope is represented 
as magenta sphere. Neighboring E proteins are shown as transparent 





3.7 HMAb 10.15 binds to DENV2 in a temperature dependent 
manner  
As expected, particles of strain NGC changed conformation after 
they were incubated at 37oC (Fig. 3-10, bottom). However, strain 
PVP94/07 remained round and smooth at temperatures up to 39°C (Fig. 
3-10, top). The varied structures of these two viruses at 37oC were 
interesting, as they had different sensitivities to neutralization by HMAb 
10.15. More importantly, the epitope of HMAb 10.15 only became fully 
accessible when the virus structure expanded, as shown in Fig 3-9b. 
The lack of structural changes in strain PVP94/07 raised the question of 
how HMAb 10.15 can bind to this virus. 
 
Figure 3-10 Cryo-EM images of uncomplexed DENV2 at different 




Very few of Fab 10.15 molecules were observed to bind to DENV2 
particles of either strain at 28oC (Fig. 3-11, left) but the numbers 
increased significantly at 37oC (Fig. 3-11, right). The binding of Fab 
10.15 to strain PVP94/07 which is visibly unexpanded at 37oC, 
suggested that the E proteins on virus may still have undergone some 
local small changes in order to expose its epitope. 
 
Figure 3-11 Fab 10.15 binds more efficiently to both DENV2 strains 
NGC and PVP94/07 at 37oC than 28oC. The white bar indicates a 
length of 50 nm. 
 
3.8 Cryo-EM structure of DENV2 –Fab 10.15 complex  
3.8.1 Single particle analysis of PVP94/07 – Fab 10.15 complex 
To understand the structural basis of HMAb 10.15 binding to 




at 37oC was used for single particle analysis. Cryo-EM projections of 
this complex revealed that the sample was heterogeneous. As the 
sample of uncomplexed virus particles at 37oC was homogeneous (Fig. 
3-10, top middle panel), such high degree of heterogeneity was likely 
contributed by the binding of Fab 10.15 and thus reflecting the flexibility 
of this complex. 
Two-dimensional classification of the particles showed two highly 
populated classes (class 5 and 18) with their averaged projections 
showing lipid bilayer separation. Together these two classes accounted 
for 68% of all particles. There were seven additional classes (class 1, 
13, 19, 20, 21, 22, and 25), which showed averaged projections of 
concentric circles each representing the nucleocapsid, lipid membrane 
and outer protein shell layers (Fig. 3-12). In total, these nine classes 
accounted for 93% of all the particles. The remaining classes with small 
number of particles and class averages showing broken particles were 
excluded from subsequent steps of 3D reconstruction. Iterative 





Figure 3-12 The 2D class averages of PVP94/07 – Fab 10.15 
complex. The number at the right bottom corner indicates the 
percentages of the particles in that particular class as a proportion of all 






Figure 3-13 Cryo-EM density map of PVP94/07 – Fab 10.15 complex. 
(a) Surface representation of the cryo-EM map of Fab 10.15 – 
PVP94/07 complex. The black triangle represents an icosahedral 
asymmetric unit and the symmetry vertices are indicated (b) A quarter 
of the cross-section of the density map showing radial density 
distribution. The map is colored radially in panels A and B: up to 160 Å, 
green; 161 Å to 220 Å, blue; 221 Å to 250 Å, cyan; above 251, red. (c) 
Resolution determination of the cryo-EM map using FSC with a 0.5 
cut-off value used. 
 
3.8.2 Single particle analysis of NGC – Fab 10.15 complex 
DENV2 Strain NGC has been shown to have greater structural 
dynamics at 37oC unlike PVP94/07. Two-dimensional classification of 
the NGC – Fab 10.15 sample also showed greater heterogeneity 




two major subsets. The first subset of classes (1, 30, 32, 33, 36, 37, 38, 
39, 41) (Fig. 3-14, green box), accounting for 46.2% of all the boxed 
particles, had similar averaged projections as those of the PVP94/07 – 
Fab 10.15 complex mentioned above (Fig. 3-12). The second subset of 
classes (class 15, 19, 20, 23, 31 and 45) had averaged projections that 
looked like broken particles (Fig. 3-14, red box). These classes 
accounted for 43.7% of all the boxed particles. A high percentage of 
broken particles could be due to surface disruption induced by binding 
of Fab 10.15, as discussed in section 3.6. 3D reconstruction using 
particles belonging to the first subset of classes resulted in the cryo-EM 
density map similar to the map obtained for PVP94/07 - Fab 10.15 






Figure 3-14 The 2D class averages of NGC – Fab 10.15 complex.  
The number at the right bottom corner indicates the percentages of the 
particles in that particular class over all particles. Only percentages 
above 1% are in this figure. The classes belonging to a subset that 
resembles PVP94/07 – Fab 10.15 are highlighted in green boxes. The 






Figure 3-15 Cryo-EM density map of NGC – Fab 10.15 complex.  
(a) Surface of the DENV2 NGC –Fab 10.15 cryo-EM map. The black 
triangle represents an icosahedral asymmetric unit and the symmetry 
vertices are indicated. (b) A quarter of the cross-section of the density 
map showing radial density distribution. The map is colored radially in 
panels A and B: up to 160 Å, green; 161 Å to 220 Å, blue; 221 Å to 250 
Å, cyan; above 251, red. (c) Resolution determination of the cryo-EM 














3.8.3 Cryo-EM structure of PVP94/07 – Fab 10.15 complex 
The map obtained from the NGC – Fab 10.15 sample was similar to 
the PVP94/07 – Fab 10.15 sample. Cryo-EM maps of both NGC – Fab 
10.15 and PVP94/07 – Fab 10.15 complexes showed protrusions of 
densities between 5- and 3-fold vertices, corresponding to the size of 
one Fab molecule, which suggested that Fab 10.15 only bound to the B 
molecule (Fig. 3-13a and 3-15a). The density corresponding to the E 
protein layer is at a radius of ~250 Å (Fig. 3-13b, Fig. 3-15b), ~10 Å 
higher than that of unexpanded mature virus particles. This indicates 
that the E protein shell may have been loosened. This is consistent with 
the observation that the Fab will clash with the neighboring E protein 
when the crystal structure Fab-E-DIII was superimposed onto the mol B 
in unexpanded mature virus structure (Fig. 3-16a). This suggests that if 
antibody is to bind to the virus, the E protein shell has to be loosened in 
order to fully expose the epitope. As the features in the cryo-EM map of 
PVP94/07 – Fab 10.15 is more obvious than NGC – Fab 10.15 complex, 
interpretation of the map by fitting in E-Fab crystal structures was only 
done for the former.  
To fit the density map, the crystal structure of the Fab10.15 – E-DIII 




the Fab density is the most obvious feature in the cryo-EM map, we first 
fitted the Fab molecule and this will guide the position of its bound E 
protein molecule B (Fig. 3-16b). The remaining density was then filled 
by the A-C’ dimer, which was moved to a higher radius and there was 
minimal rotation (Fig. 3-16c, d).  
 
Figure 3-16 Fitting of PVP94/07- Fab10.15 into cryo-EM density 
map. Superimposition of the Fab 10.15 – E-DIII crystal structure to mol 
B in the unexpanded mature virus structure (PDB code 3J27) showed (a) 
clashes of the Fab with mol A, highlighted by the dotted pink circle. (b) 
Side view of the Fab molecule at map contour level of 2. Top views of 
the fitting with (c) E proteins at map contour level of 3.5 and, (d) E 
proteins and Fab molecules at map contour level of 2.0. The cryo-EM 




as yellow ribbon and E protein mols A, B and C on virus surface are 
colored in blue, red and green, respectively. 
 
The fitted E protein suggested that upon binding of Fab 10.15 to B 
molecule, this E protein adopted a different conformation from that in 
unexpanded mature virus structure (Fig. 3-17a). In general, all E 
proteins had moved to a higher radius compared to the unexpanded 
structure. However, the E protein arrangement of the DENV2 PVP94/07 
– Fab 10.15 structure was more similar to the compact unexpanded 
NGC structure than the expanded structure (Fig. 3-17b).  
In summary, HMAb 10.15 was able to bind to B molecule, but not A 
and C molecules of PVP94/07. Binding of Fab 10.15 to B molecule led 
to the dissociation of the B-B’ dimer and the loosening of the E protein 
shell.  
 
Figure 3-17 Comparison of PVP94/07 – Fab 10.15 structure with 




the fitted structure with the unexpanded mature virus structure at 28oC. 
A, B and C molecules and A’, B’ and C’ molecules are labeled. The 
triangle indicates one asymmetric unit. (b) Side view of the A, B and C 
molecules in different structures with the E-DIII side facing out. Different 
structures are colored as the color key. All molecules are shown with Cα 
chains. 
3.9 Neutralization mechanism by HMAb 10.15 
HMAb 10.15 was more potent against DENV2 strain NGC than 
PVP94/07 (Fig. 3-8, Table 3-4). Analysis of both cryo-EM samples 
revealed varied extents of structural heterogeneity of particles in the 
samples and DENV2 strain NGC – Fab 10.15 complex sample showed 
higher heterogeneity. The higher neutralization activity of HMAb 10.15 
towards NGC strain than to PVP94/07 (Table 3-4) correlated with the 
bigger population of particles in the NGC strain that expand in structure 
which lead to an increased in the accessibility of epitope. The 
reconstructed structures for both complexes probably only represented 
the particles which did not expand at higher temperatures.  
3.9.1 IgG 10.15 is unable to bind bivalently to PVP94/07  
Distances between the CH1 domain C-termini of Fab 10.15 were 
measured for each pair of Fab molecules bound on the virus surface. A 
maximum distance between two Fab arms within the same IgG 
molecule is unlikely to be over 87 Å according to the currently available 




separation for Fab 10.15 on the cryo-EM structure was 93 Å, indicating 
that bivalent binding of 10.15 IgG to the same particle is unlikely to 
occur (Fig. 3-18a). There were about 60% of particles from the NGC – 
Fab 10.15 sample, which were broken or are too flexible for single 
particle reconstruction. It is possible that these particles may have 
higher Fab occupancies and thus higher number of available epitopes. 
Since there is a lack of structural information on these virus populations, 
bivalent binding of IgGs on those particles could not be analyzed.  
3.9.2 IgG 10.15 is unable to aggregate PVP94/07 
 Since 10.15 IgG has higher neutralization activity than its Fab 
molecule, we investigated the ability of IgG 10.15 to aggregate 
PVP94/07. Dynamic light scattering (DLS) was used to measure the 
size of IgG – DENV2 complex. The hydrodynamic size of DENV2 (strain 
PVP94/07) was determined to be 71.20±2.51 nm in radius, similar to 
the previous finding (Watanabe et al., 2015). The size of full length IgG 
molecule was determined to be ~12 nm in radius.  
The experiment was done using various molar ratios of IgG to 
individual E proteins on virions (i.e. each potential antibody binding site) 
ranging from 9:1 to 1:480. When another DENV2-specific neutralizing 




complex increased dramatically and peaked at ~250 nm with a 
polydispersity index (PDI) of 0.3 at molar ratio of 3:1. There were 
aggregations formed at both 1:1 and 3:1 molar ratios (Fig. 3-18b).  The 
relatively low PDI indicated formation of stable aggregates with similar 
sizes. At even higher IgG to E molar ratio of 9:1, the size of the immune 
complex decreased, suggesting that at this ratio, the excess antibodies 
did not cross-link virions, therefore no aggregates were formed.  
In contrast, when the virus was mixed with the antibody 10.15, the 
size of IgG 10.15 – PVP94/07 complex only mildly increased (Fig. 
3-18c). The size increase of this immune complex was modest 
throughout the entire range of molar ratios tested. The maximum 
change of the size was close to 30 nm, which corresponded to the size 
of IgG molecules coated on the surface of the virion. This result 





Figure 3-18 IgG 10.15 is unable to bind bivalently to PVP94/07. 
(a)The possibility of bivalent binding of both Fab arms of IgG 10.15 to 
one PVP94/07 particle was evaluated based on the cryo-EM structure. 
Distances between two adjacent Fab molecules are labeled. They are 
all larger than the maximum distance between two Fab of an IgG 
molecule (approximately 87 Å, calculated from the available full-length 
IgG structure (PDB code 1IGT)). Size measurement of PVP94/07 
complexed with IgG of (b) HMAb 10.15 and (c) 2D22 at a series of 
antibody-virus ratios. The size of one virus particle alone is highlighted 











Chapter IV. DENV2-specific Neutralizing HMAb 3F9  
4.1 HMAb 3F9 could bind to recombinant DENV2 E protein but not 
E-DIII  
HMAb 3F9 is a DENV2-specific neutralizing HMAb isolated from 
memory B cell of a patient recovered from a primary dengue infection 
(Smith et al., 2014). Preliminary data had shown that this antibody can 
neutralize DENV2 very efficiently in flow cytometry-based neutralization 
assays, with a PRNT50 value of 30 and 3 ng/ml by using U937 cell 
expressing DC-SIGN and Vero-81 cell, respectively. Moreover, this 
antibody did not enhance viral infection at a concentration of 1.0 μg/ml 
in a flow cytometry-based ADE assay.  
As shown in Fig. 4-1, HMAb 3F9 recognized recombinant DENV2 E 
protein, but did not bind to E-DIII in an indirect ELISA assay. As controls, 
an anti-DIII murine MAb 1A1D-2 bound to both recombinant E protein 
and E-DIII, whereas an anti-prM murine MAb 2H2 did not recognize 





Figure 4-1 HMAb 3F9 only binds to recombinant E protein but not 
E-DIII. Binding of mouse monoclonal Ab 1A1D-2 and 2H2 and, HMAb 
3F9 to recombinant DENV2 E and E-DIII. BSA was employed as a 
control antigen in this indirect ELISA. 
4.2 IgG 3F9 potently neutralize both DENV2 strains NGC and 
PVP94/07 
There was a significant difference (P < 0.001) in the PRNT50 value 
for IgG 3F9 against DENV2 strain NGC (2.5 ± 0.2 ng/ml) and strain 
PVP94/07 (12.2 ± 1.7 ng/ml) (Fig. 4-2 left, Table 4-1). Comparable 
amounts of Fab were required to neutralize both virus strains 
(PRNT50(NGC), 3.4 ± 2.5 ng/ml; PRNT50(PVP94.07), 31.7 ± 14.7 ng/ml) 






Figure 4-2 Neutralization of DENV2 strains NGC and PVP94/07 by 
3F9 IgG and Fab in BHK-21 cell. Neutralizations of 50% and 90% of 
the infectivity were highlighted by dashed lines. All experiments were 
repeated at least three times with duplicates and one of the 
neutralization curves is shown here.  
 




 (PVP94/07 : 
NGC) 
Fab  3.4 ± 2.5 31.7 ± 14.7 9.3 
IgG  2.5 ± 0.2 12.2 ± 1.7 4.9 
 (Fab : IgG) 1.4 2.6 
 
 
4.3 HMAb 3F9 binds to DENV2 PVP94/07 at 4oC 
DENV2 strain PVP94/07 has been previously shown to remain 
smooth and unexpanded at temperatures up to 39oC (Fig. 3-10). In this 
study, Fab 3F9 was found to bind to PVP94/07 at 4oC (Fig. 4-3), 




surface therefore E protein motion was not required for its binding. i
 
Figure 4-3 HMAb 3F9 can bind to PVP94/07 at 4oC. Micrographs 
showing a control with DENV2 strain PVP94/07 grown at 28oC followed 
by incubation at 4oC (left) and DENV2 PVP94/07 complexed with Fab 
3F9 at 4oC (right). The complex appeared to be round but spiky. White 
bars indicate a length of 50 nm.  
4.4 Cryo-EM structure of PVP94/07 – Fab 3F9 complex 
The cryo-EM density map of the PVP94/07 – Fab 3F9 complex was 
determined to be 22-Å in resolution (Fig. 4-4e). The density 
corresponding to the Fab molecule was clearly resolved as a 
two-domain structure, representing the constant and variable regions of 
one Fab molecule) (Fig. 4-4a). The separation of the viral lipid bilayer 
was also clearly resolved (Fig. 4-4c). The E protein layer remained 
nearly at the same radius, ~240 Å, as the DENV2 mature virus at 28oC 




visible in this map (Fig. 4-4a). In addition, there was a bump above 
every 3-fold vertex, reaching a higher radius than the virus surface, 
which corresponded to the size of the variable region of a Fab molecule. 
This could be one Fab molecule binding to one of the three individual E 
proteins proximal to the 3-fold vertex (Fig. 4-4a). Some densities were 
visible at a higher radius above these bumps but only at a lower contour 
level (Fig. 4-4b, d). These smeared densities might correspond to the 
constant region of the Fab molecule. The weakened densities might be 
due to icosahedral averaging approach during the 3D reconstruction 
since each of the Fab molecules was likely to have different orientations 





Figure 4-4 Cryo-EM density map of PVP94/07 – Fab 3F9 complex. 
Cryo-EM density map of PVP94/07 – Fab 3F9 complex at a contour 
level of (a) 2.5 and (b) 2. The virus surface is colored in cyan and the 
Fab 3F9 is colored in red (constant region) and yellow (variable region). 
The black triangle represents an icosahedral asymmetric unit and the 
numbers label the symmetric vertices. At (b), a slightly lower contour 
level showed the weaker density on top of the 3-fold vertex with the 
arrow pointing to it. (c) A quarter of the cross-section of the density map, 
showing radial density distribution. The map is colored radially in panels: 
green (up to 160 Å), blue (161- 200 Å), cyan (201-235 Å), yellow 
(235-260), red (above 261 Å). (d) Side view of the weak density on top 
of the 3-fold vertex with an arrow pointing to it. (e) FSC (gold-standard) 
versus resolution plot was shown with green line highlighted where FSC 
= 0.5. 
 
Interpretation of the cryo-EM density map was carried out by fitting 
the DENV2 unexpanded mature virus structure (PDB code 3J27) and 
an atomic model for the Fab, considering that the overall shapes of the 
Fab molecules for HMAbs were usually conserved. The mature virus 
structure fitted nicely to the cryo-EM density map of PVP94/07 – Fab 
3F9 complex, with the structure of E protein raft being preserved (Fig. 
4-5a). In addition, the densities corresponding to the transmembrane 
domains of E and prM proteins matched with the unexpanded mature 
virus structure (Fig. 4-5c). These results together indicated that binding 
of Fab 3F9 did not induce significant structural changes of the virus 
surface. Fitting of the Fab molecule was guided by the clear separation 




In this fitting, 3F9 was shown to bind to A and B molecules (Fig. 
4-5b). The Fab 3F9 bound to C molecule was omitted from the fitting 
since its density was much poorer. Furthermore, the smeared and 
weaker density made the determination of its orientation ambiguous. 
However, the handedness of the Fab molecules (i.e. the differentiation 
of its heavy and light chains) relative to the E protein could not be 
confidently determined at this resolution. The density of the variable 
region was stronger than that of the constant region in our density map, 
indicating a greater flexibility of the constant region, similar to the 





Figure 4-5 Fitting of the PVP94/07 – Fab 3F9 into the cryo-EM map. 
Views with the cryo-EM density map fitted with (a) the E protein raft of 
mature virus structure at 28oC, (b, d) a model for Fab 3F9 binding on the 
virus surface, and (c) transmembrane domains of both E and prM 
proteins. The map was rendered at a contour level of 3.5 for (a) and 2 
for (b, c, d), respectively. E protein A, B and C molecules within one 
asymmetric unit are colored in blue, red and green, respectively. The 
prM proteins paired with A, B and C molecules are colored in light blue, 
orange and dark green, respectively. The Fab molecules are colored in 
yellow. The black triangle labels one asymmetric unit and the 
arrowheads in (c) highlight the positions of the transmembrane 
domains. 
4.5 Epitope recognized by 3F9 




models into the cryo-EM map (Fig. 4-6b, c). Footprint of the Fab was 
restrained to a single E protein, which was consistent with the 
observation that 3F9 could bind to recombinant E protein (Fig. 4-1). 
HMAb 3F9 largely bound to DI and possibly the linker region between 
E-DI and E-DIII (Fig. 4-6b, c). Since these regions in three C molecules 
proximal to one 3-fold vertex were close to each other, it would not be 
possible for the Fab 3F9 to bind to more than one of the three C 









Figure 4-6 The epitope recognized by 3F9. 
(a) One asymmetric unit on mature virus surface was shown with A, B 
and C molecules shaded. E-DI, II and III are colored as yellow, red and 
blue, respectively. The estimated binding areas in E-DI of (b) mol A and 
(c) mol B were colored as magenta with the DI-III linker labeled. The 
Fab molecule is colored green. (d) Clashes of three Fab molecules 
superimposed to three C molecules around one 3-fold vertex. The three 
Fab molecules are colored as green, cyan and grey, respectively with 







Chapter V. Summary, General Discussion and Future 
perspective  
In this study, we have identified the epitope for two DENV2 specific 
HMAb 10.15 and 3F9 by a combination of structural and biochemical 
methods. Unlike previously defined epitopes for neutralizing HMAbs, 
both antibodies recognized epitopes which were restricted to the E 
protein monomer and not quaternary structure-dependent (Fig. 3-4, Fig. 
4-6). While HMAb 3F9 bound to an exposed epitope located in E-DI, 
HMAb 10.15 recognized a partially hidden epitope on E-DIII. The study 
of interaction between HMAb 10.15 and DENV2 revealed that structural 
variation of DENV can affect the neutralizing potency of Abs. This study 
also showed that Fab fragment of 3F9 had a comparable potency as its 
IgG form, whereas Fab 10.15 was much weaker compared with its 
full-length IgG in neutralization. Further experiments revealed that the 
higher potency of IgG 10.15 was not due to its ability to aggregate virus 
particles. The crystal and cryo-EM structures reported in this thesis 
provided a structural basis for a comprehensive understanding of 
neutralization of DENV by HMAbs. 




Significant number of human serotype-specific neutralizing 
antibodies target quaternary structure-dependent epitopes that are only 
present on the intact virion (Fibriansah et al., 2015b, Fibriansah et al., 
2014, Teoh et al., 2012, Kaufmann et al., 2010, de Alwis et al., 2012). 
This type of antibodies cannot recognize recombinant E protein. Also, 
the binding of these antibodies depends on either the quaternary 
arrangement of E proteins or the specific conformation of E protein on 
the virus surface. In this study, we found two neutralizing HMAbs which 
could recognize not only intact virus but also recombinant E protein. 
More recently, another class of neutralizing HMAbs, which binds to the 
E-dimer-dependent epitopes (EDE), has been isolated and 
characterized (Rouvinski et al., 2015, Dejnirattisai et al., 2015, 
Fibriansah et al., 2015a). Epitopes for this class of antibodies typically 
span the E-dimer with contact residues in all three domains of the E 
proteins. Unlike the EDE antibodies, epitopes recognized by 3F9 and 
10.15 are restrained to one E protein monomer.  
HMAb 3F9 would be the third antibody that recognizes E-DI with an 
antigen-antibody structure available so far. The other two antibodies, 
5H2 and 1F4, are isolated from chimpanzee and human, respectively 




similar target area in E-DI as the DENV4-specific chimpanzee MAb 5H2. 
This is different from the DENV1-specific HMAb 1F4, which binds more 
to the side of the E-DI/II hinge region (Fig. 5-1). This subtle difference of 
their epitopes is also reflected by their binding abilities to the 
recombinant E protein. While 3F9 and 5H2 are able to bind to 
recombinant E protein, 1F4 cannot recognize recombinant E protein 
since it is sensitive to the DI/II hinge angle which is different between 
recombinant E protein and E protein on an intact virion. Because 
determination of the precise epitope for 3F9 could not be accomplished 
by the cryo-EM structure at this relatively low resolution (~22-Å), we 
cannot precisely compare its epitope with the epitope of 5H2. Our 
cryo-EM structure of PVP94/07 – Fab 3F9 complex was similar to the 
DENV – Fab 5H2 complex structure estimated by docking experiment. 
However, our cryo-EM structure also revealed unexpected occupancy 
of 3F9 on C molecule proximal to the three-fold vertex of the virion (Fig. 
4-4). Epitope of 5H2 on molecule C was predicted to be slightly buried 
by neighboring E proteins. Since Fab 3F9 was observed to be able to 
bind to molecule C, the epitope of 3F9 might be slightly different from 
5H2. There was also a possibility that even at 4oC, Fab 3F9 could pull 





Figure 5-1 Comparison of E-DI binding antibodies.  
Side views of the E protein- Fab complexes of antibody 3F9, 5H2 and 
1F4. E protein was shown as ribbon with domain I, II and III colored in 
red, yellow and blue, respectively. Fab of 5H2, 3F9 and 1F4 are shown 
as cyan, green and pink ribbons, respectively. The DI/II hinge, which is 
critical for 1F4 binding, is highlighted. 
 
Another antibody, HMAb 10.15, was found to bind to E-DIII (Fig. 
3-1). Anti-DIII antibodies make up one category of the most highly 
neutralizing antibodies against flavivirus. Two well-characterized E-DIII 
epitopes are lateral ridge and A-strand, with crystal structures revealing 
the details of binding interfaces and also cryo-EM structures showing 
the overall arrangement of antibodies on the virus surface. Epitope of 
lateral ridge antibodies, for example, E16, is located on the upper face 
of the E-DIII and is mainly comprised of residues in four discontinuous 
loops (Nybakken et al., 2005). This epitope is fully exposed on all three 




but at saturating concentration, only 120 copies of Fab molecules can 
bind to one virion with no Fab bound to the E-DIII close to the 
icosahedral 5-fold vertex (Kaufmann, 2006). A-strand epitope is mainly 
centered on A-strand and partially hidden from virus surface. One of the 
A-strand antibodies, 1A1D-2, can bind to the virus at 37oC but not 28oC 
because ~18% of its epitope is buried by neighboring E proteins (Lok et 
al., 2008). Binding of its Fab to the virion results in a dramatic 
conformational change of the virus surface with an occupancy of 120 
Fab molecules per virion. The epitope of HMAb 10.15 is close to 
A-strand, with another major part of it located in G-strand and FG loop 
(Fig. 5-2a). This subtle difference of the epitope caused HMAb 10.15 to 
adopt a different orientation from the A-strand antibodies when bound to 
the E protein (Fig. 5-2b). This could potentially explain the difference of 
occupancies of these two antibodies on the virus surface and to which 
particular E proteins these two antibodies bind. 
 




antibody 1A1D-2. (a) E protein is shown as ribbon with domain I, II and 
III colored in blue, red and yellow, respectively. Residues only in the 
epitope of 1A1D-2, only in the epitope of HMAb 10.15, and shared by 
both epitopes are shown as green, pink and orange spheres, 
respectively. (b) 10.15 (pink) and 1A1D-2 (green) bind to E protein (grey) 
at different orientations. All proteins are shown as surfaces. Crystal 
structure of Fab 1A1D-2 – E-DIII (PDB code 2R69) and Fab 10.15 – 
E-DIII are superimposed to the E protein structure (PDB code 1OAN). 
5.2 Structural basis for antibody neutralization 
Anti-flavivirus antibodies have been shown to neutralize the virus by 
mechanisms such as blockage of virion attachment to target cells, 
destabilization of the virion, and inhibition of fusion between viral and 
host cell lipid membranes. Neutralization mechanism is determined by 
the properties of both antibody and its epitope on the virion.  
The epitope of HMAb 10.15 in E-DIII has been suggested to have 
important functions in virus infection. Residues located in A-strand have 
been suggested to be involved in attachment and receptor recognition 
since mutations of some of these residues can greatly attenuate the 
virus (Holzmann et al., 1990, Mandl et al., 2000, Lee et al., 2013). 
Residues 383-384 (located in FG loop) that is only present in 
mosquito-borne but not tick-borne flaviviruses have also been proven to 
be critical for infection (Erb et al., 2010). Therefore, HMAb 10.15 might 




Moreover, binding of HMAb 10.15 to the virus forced the B-B’ dimer to 
fall apart, resulting in changes of the relative position between A, B and 
C molecules. This might affect the binding of the virus to its attachment 
factors or receptors. For example, binding of DENV to DC-SIGN, one of 
the receptors in dendritic cells, requires the glycans subtly arrayed on 
the neighboring E proteins, which depends on the quaternary structure 
of the virion (Pokidysheva et al., 2006).  
Mechanisms of fusion inhibition have been postulated based on the 
crystal structures of E protein homotrimers at low pH with and without 
the presence of the stem region (Modis et al., 2004, Bressanelli et al., 
2004, Nayak et al., 2009, Klein et al., 2013) and some in-vitro fusion 
assays with synthetic liposome (Stiasny et al., 2007). The proposed 
mechanisms include interference with the relocation of DIII for hairpin 
formation, trimer formation, cooperative interactions of E homotrimers 
(suggested for enlargement of the fusion pore) and direct blocking of 
the fusion loop (Stiasny et al., 2007) (Fig 5-3a). E-DIII relocates in the 
fusogenic conformation by a substantial swing-around movement of the 
DI-III linker (Fig. 5-3b). Since the 3F9 contacted residues located in the 
DI-III linker region, it may be able to stabilize the DI-III linker to prevent it 




DI in the Fab 3F9 – E protein from the cryo-EM structure to the 
post-fusion trimeric E protein structure (PDB code 1OK8) showed 
significant clashes of the Fab molecule with the DIII from one of the 
adjacent E protein (Fig. 5-3c). This suggested that once Fab 3F9 was 
bound to the virus, the E protein would not be able to form the fusogenic 
post-fusion trimeric spike. This hypothesis is supported by the fact that 
anti-DI antibody 5H2, which recognizes a similar epitope, has been 
shown to inhibit virus fusion with lipid membrane at low pH (Cockburn et 
al., 2012b). In summary, binding of HMAb 3F9 would prevent the 
formation of the fusogenic trimer, therefore neutralizing the virus by 
inhibiting its fusion process. In contrast, for HMAb 10.15, 
superimposition of the Fab 10.15 – E-DIII co-crystal structure with E-DIII 
to the post-fusion E protein trimeric structure did not show any clashes 
between the Fab molecule and adjacent E proteins within the same 
trimer (Fig. 5-3d). However, the possibility that binding of HMAb 10.15 
might interfere with fusion in other steps, such as clashes with adjacent 
trimeric spikes during the process of enlargement of the fusion pore, 





Figure 5-3 Interference of the fusion process by 3F9 and 10.15 
(a) Schematic model of the flavivirus fusion process (A to E). E-DI, red; 
E-DII, yellow; E-DIII, blue; fusion loop, orange; stem, purple; 
transmembrane anchor, green; viral membrane, blue; target membrane, 
grey. (A) E dimer on the mature virus surface. (B) Low pH-induced 
dissociation of the dimer and insertion of the fusion loop into the target 
membrane. (C) Relocation of DIII leading to hairpin formation, 
trimerization, and zippering of the stem along the trimer. (D) Hemifusion 
intermediate. (E) Fusion pore formation. Figure extracted from Stiasny, 
K., et al. J Virol (2007). 
(b)The DI-DIII linker flexes and the DIII was relocated in the post-fusion 
trimeric structure of E protein (PDB code 1OK8). DI, II and III of E 
protein on the mature virus surface (PDB code 3J27) are colored in red, 
yellow and cyan, respectively. E-DIII in the post-fusion crystal structure 
is colored in blue. (c) Superposition of DI in the Fab 3F9 – E protein 
cryo-EM structure to the post-fusion trimeric E protein structure showed 
significant clashes between the Fab and DIII of a neighboring E protein. 
Two E proteins are shown as surfaces (colored in light and dark gray) 
and another is shown as ribbons. Fab 3F9 is drawn as a green surface. 
(d) Superimposition of Fab 10.15 - E-DIII crystal structure onto the 
post-fusion trimeric spike. The Fab molecule points away from the 
trimeric E protein. Three individual E proteins in the trimer are shown as 





5.3 Structural dynamics, epitope accessibility, occupancy and 
antibody potency 
DENV2 undergoes structural changes at temperatures above 33oC 
(Zhang et al., 2013). One class of expanded structures, shows an 
expansion of the E protein layer, lifting up of DIII of molecule B and 
formation of holes at the 3-fold vertices of the virion (Fig. 3-9b). 
Previous studies have suggested a role of structural dynamics of DENV 
in antibody-mediated neutralization (Austin et al., 2012, Zhou et al., 
2013). 
The impact of the structural dynamics on antibody recognition has 
been discussed for some antibodies recognizing hidden epitopes 
(Fibriansah et al., 2013). In this study, the epitope of HMAb 10.15 was 
mapped to one of the expanded structures, showing that the epitope on 
B molecule have become fully exposed (Fig. 3-9b).  Surprisingly, 
although DENV2 PVP94/07 does not seem to change its structure at 
37oC, Fab 10.15 could still bind to the virus particle (Fig. 3-11). Binding 
of Fab 10.15 to NGC strain is easier to understand since this virus is 
expanded at a higher temperature, leading to exposure of the otherwise 
partially hidden epitope. On the other hand, the explanation of how Fab 




less dynamic and insensitive to temperature change. There are two 
hypotheses to explain the binding of HMAb 10.15 to these unexpanded 
virus particles.  
The first hypothesis is that these unexpanded virus particles do 
expand, but their expansions are reversible, so the epitopes are only 
exposed transiently. In our cryo-EM experiment, incubations of the 
viruses at different temperatures were typically followed by a 2-hrs 
4oC-cooling step before the sample was plunged-frozen to liquid 
nitrogen temperature. This step was included to equilibrate the sample 
to lower temperatures to facilitate formation of vitrified ice which can 
preserve the native structure of the sample. During this cooling step, it 
is possible that the virus particles alone can recover to the unexpanded 
state.  
There is also another possible explanation for the binding of HMAb 
10.15 to the unexpanded virus particles of DENV2 strain PVP94/07. 
The second hypothesis is that the interaction between Fab 10.15 and its 
epitope is much stronger than that between the E proteins. As a result, 
upon binding, Fab 10.15 was able to pull out and rotate the E protein B 
molecule on the virus surface. This exposed the previously partially 




DENV2 strains NGC and PVP94/07 have different susceptibilities to 
HMAb 10.15 neutralization. The neutralization of the structurally more 
stable strain, PVP94/07, requires at least 10 times higher antibody 
concentration, regardless of IgG or Fab used (Table 3-4). This 
difference in potencies was proved to be only due to the structural 
difference between these two viruses instead of the variation in their 
binding affinities. 
All previously-characterized neutralizing antibodies against 
flavivirus have an occupancy of at least 120 Fab molecules per virion 
(Kaufmann, 2006, Kaufmann et al., 2010, Lok et al., 2008, Teoh et al., 
2012, Fibriansah et al., 2014, Fibriansah et al., 2015b, Fibriansah et al., 
2015a, Dejnirattisai et al., 2015). One exception is a DENV3-specific 
HMAb, 5J7, which binds to the virion at an occupancy of 60 Fab 
molecules per virion at saturation levels but can grabs three E proteins 
at the same time by one single Fab molecule (Fibriansah et al., 2015b). 
As a result, this antibody is able to lock the virus and prevent it from 
undergoing conformational changes required for viral fusion process. In 
our study, the cryo-EM structure of PVP94/07 – Fab 10.15 complex 
revealed an occupancy of 60 Fab molecules on one virus particle at 




sample also showed the same occupancy (Fig. 3-15a). It should be 
noted that not all particles in strain NGC undergo conformational 
changes at 37oC. In previous study, there are still about 20% of the 
particles which are not expanded (Fibriansah et al., 2013). However, for 
the expanded virus particles of DENV2 strain NGC, as the E protein 
layer on the virus surface is loosened, the antibody has a higher chance 
of binding to more E proteins on the virus surface. Binding of the 
antibody on these particles might be able to disrupt the E protein 
structure since the surface protein interaction in these particles is 
weaker. This might contribute to the formation of the broken particles 
observed in the experiment (Fig. 3-14). Moreover, there is another class 
of virus particles in which their E proteins have probably flexed up 
(Fibriansah et al., 2013). This class might have more binding sites 
available for HMAb 10.15. Thus, HMAb 10.15 might be able to bind to 
strain NGC at a higher occupancy, but the structures of these particles 
were probably too heterogeneous to be resolved.  
5.4 IgG of HMAb 10.15 is more potent than its Fab  
To our knowledge, the neutralizing ability of IgG against virus is 




can vary widely. For example, HMAbs 1F4 and 5J7, neutralize the virus 
4-fold and 8-fold more potently in their full-length IgG forms than their 
Fab fragments (Fibriansah et al., 2014, Fibriansah et al., 2015b). 
However, for antibody E106, the potency of its Fab is 18150-fold lower 
than its IgG (Edeling et al., 2014). The bivalent binding ability of IgG 
E106 was demonstrated to be important for its neutralizing ability, as 
the affinity of its Fab is only at micromolar range. The epitope of E106 in 
molecules A, B and C within one asymmetric unit are all exposed on the 
virus surface and close to each other, allowing for bivalent binding of its 
IgG form, which compensates for the relatively low affinity of its Fab.  
In this study, there was an approximately 100-fold difference in the 
potencies of HMAb 10.15 between its IgG and Fab (Table 3-4). In 
comparison, the Fab fragment of 3F9 could neutralize the virus as well 
as its full-length IgG. Fab 3F9 was apparently much more potent 
compared to Fab 10.15 against the same virus strain. For example, 
PRNT50 of Fab 3F9 against NGC was 3.4 ± 2.5 ng/ml, whereas for Fab 
10.15, PRNT50 value was 293.6 ± 67.5 ng/ml (Table 3-4). The fact that 
Fab 3F9 neutralized better compared to Fab 10.15 could be possibly 
due to its higher occupancy on the virus surface, as shown by the 




The higher potency of IgG 10.15 compared with its Fab fragment 
could be due to several reasons: (1) bivalent binding to single virion and 
cross-link the virus surface; (2) aggregation of virus particles; (3) 
increase of the steric hindrance to virus – host interactions (such as 
receptor binding or virus fusion) due to its larger size; (4) bivalency of 
the IgG which can increase the chance for a second binding to an 
otherwise hidden epitope site. It should be noted that cryo-EM 
structures of antibody – virus complexes which have been solved so far 
were mostly using Fab or scFv (single chain variable fragment) instead 
of full-length IgG. This might not reveal the real binding situation which 
happens in the virus –IgG complex since IgG has two Fab arms and is 
also larger in size.  
Whether the IgG can bind bivalently to the same virion depends on 
several factors: the span of its two Fab arms, the distance between its 
epitopes on the virus and the dynamics of the virus structure. Our 
analysis showed that IgG 10.15 is unlikely to bind bivalently to the same 
virion at least for particles of strain PVP94/07 (Fig. 3-18a) whereas for 
HMAb 3F9, IgG bivalent binding is possible for a few neighboring 
binding sites on individual E proteins (Fig. 5-4), which might cross-link 






Figure 5-4 The possibility of bivalent binding of IgG 3F9 to DENV2.  
Orange lines indicate epitope that are close enough there likely to allow 
both Fab arms to be engaged simultaneously. Magenta lines indicate 
epitopes that are further apart therefore unlikely to allow bivalent 
binding. Distances of both orange and magenta lines are indicated. The 
maximum distance between two Fab of an IgG molecule (approximately 
87 Å) is calculated from the available IgG structure (PDB code 1IGT). 
Measurement was based on the Fab 3F9- PVP94/07 complex cryo-EM 
structure. The handedness of the Fab was arbitrarily chosen and 
distances between two CH1 termini were measured.   
 
Aggregation is another important potential neutralization 
mechanism, which reduces the number of virions able to initiate an 
infection. Aggregates form when many virus particles are stably 
cross-linked by multivalent antibodies. IgG can aggregate viruses by 




antibodies. Measuring the size profile of PVP94/07 in complex with IgG 
10.15 showed that IgG 10.15 is unable to aggregate PVP94/07, in 
contrast with another potent DENV2 specific HMAb 2D22 (Fig. 3-18b, c). 
Since IgG 10.15 does not bind bivalently to the same virion according to 
the current cryo-EM structure or aggregate the viruses, the increase of 
its potency comparing to Fab can be purely due to its larger size. When 
one arm of the IgG binds to the virus, the rest of the antibody can cover 
a larger area of the virus surface, leading to a greater steric obstruction, 
which can prevent the virus from binding to its attachment factor or 
receptor. This could be particularly important for antibodies like HMAb 
10.15, which could not bind to virus at high occupancy. Another 
potential explanation is that due to the bivalency of the IgG molecule, 
binding of one Fab arm to the virus can increase the chances of binding 
of the other arm to a previously-hidden epitope site, therefore resulting 
in bivalent binding, which is not captured in our current cryo-EM 
structure of virus – Fab 10.15 complex. 
5.5 Future perspectives 
Some studies have observed strain/genotype -wide differences of 




al., 2010). We have found in this study that an antibody which targets a 
partially hidden epitope was less neutralizing against a structurally more 
stable virus strain PVP94/07 compared with the more dynamic strain 
NGC. This finding provides direct evidence that structural dynamics of 
DENV affects antibody potency. Considering that the neutralization 
assay for evaluation of antibody neutralizing ability often only includes 
very limited virus strains with unclear structural backgrounds, this thesis 
highlights the structural variation of different DENV strains and 
emphasizes the importance of accounting for structural differences of 
virus strains in the future design of antibody function assay.   
In this study, both HMAb 10.15 and 3F9 target epitopes on 
E-monomer and their bindings are not dependent on either the E protein 
dimeric structure or the quaternary arrangement of the whole virion. As 
DENV particles have been shown to be heterogeneous in structure: the 
unexpanded mature virus, the expanded mature virus, the partially 
mature virus and fully immature virus. Further studies need to be 
conducted to investigate whether the antibodies characterized so far 
can neutralize these structurally different DENV particles. The results 
will be constructive in answering the question of whether a single type 




DENV infection. The two E-monomer targeting DENV2-specific 
neutralizing HMAbs in this study might be a good supplement to the 
arsenal of DENV antibody therapeutics.  
Since the structural variation of different DENV strains can affect 
antibody potency, it would be interesting to investigate the extent of its 
impact not only with isolated monoclonal antibodies, but also with 
polyclonal antibodies or even human serum from DENV-infected 
patients. This could help answer the question of whether antibody 
response stimulated by virus strains with one particular structure can 
also potently neutralize structurally different strains and protect human 
from re-infection with these strains. These studies can potentially 
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